Search by Journal
- HOME
- > Search by Journal
- > Journal of Japanese Society of Pharmaceutical Oncology
Journal of Japanese Society of Pharmaceutical Oncology
Volume 30, Issue / 2023
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
The future of regional medical collaboration that stands by and supports patients 大塚昌孝 Journal of Japanese Society of Pharmaceutical Oncology 30: 1-1, 2023. |
|---|
|
|
Activity report in 2022 and the shape of JASPO's future 近藤直樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 2-2, 2023. |
|---|
|
|
The training of the pharmacist contributing to cancer medical therapy 山田清文 Journal of Japanese Society of Pharmaceutical Oncology 30: 3-3, 2023. |
|---|
|
|
A teacher, morphine work well. Why is the medicine for cancer not so? : Cancer treatment which we examined from the remote place 江角浩安 Journal of Japanese Society of Pharmaceutical Oncology 30: 4-4, 2023. |
|---|
|
|
The road to becoming a pharmacist specializing in outpatient cancer treatment starting from scratch! 縄田修一, 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 30: 5-5, 2023. |
|---|
|
|
S1-1. Authorization, specialized system of Japanese clinical tumor Pharmaceutical Society 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 30: 6-6, 2023. |
|---|
|
|
S1-2. Point of the case accumulation necessary for the application of the foreign cancer treatment authorization pharmacist 下川友香理 Journal of Japanese Society of Pharmaceutical Oncology 30: 7-7, 2023. |
|---|
|
|
S1-3. About the interview examination of the foreign cancer treatment authorization pharmacist 小室雅人 Journal of Japanese Society of Pharmaceutical Oncology 30: 8-8, 2023. |
|---|
|
|
S1-4. Summary of the cancer practice hospital cooperation training 縄田修一1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 9-9, 2023. |
|---|
|
|
S1-5. Point during the cancer practice hospital cooperation training 衛藤智章 Journal of Japanese Society of Pharmaceutical Oncology 30: 10-10, 2023. |
|---|
|
|
S1-6. The distance to a pharmacist specialized in foreign cancer treatment 牧原直 Journal of Japanese Society of Pharmaceutical Oncology 30: 11-11, 2023. |
|---|
|
|
The pharmacist will try cancer medical treatment of elderly people and relation ... elderly people usability test of the pharmacist, too 井上裕貴, 村田勇人 Journal of Japanese Society of Pharmaceutical Oncology 30: 12-12, 2023. |
|---|
|
|
S2-1. Expectation to elderly people usability test and a pharmacist 安藤雄一 Journal of Japanese Society of Pharmaceutical Oncology 30: 13-13, 2023. |
|---|
|
|
S2-2. When is at a loss; how to use - of element display - elderly people usability test tool 市村丈典 Journal of Japanese Society of Pharmaceutical Oncology 30: 14-14, 2023. |
|---|
|
|
S2-3. Onset of adverse event prediction by the elderly people usability test 内山将伸 Journal of Japanese Society of Pharmaceutical Oncology 30: 15-15, 2023. |
|---|
|
|
Cancer medical therapy of the electronic prescription era 和田敦, 小枝伸行 Journal of Japanese Society of Pharmaceutical Oncology 30: 16-16, 2023. |
|---|
|
|
S3-1. It is ... from the situation of current situation and problem ... hospital of the electronic prescription 舟越亮寛 Journal of Japanese Society of Pharmaceutical Oncology 30: 17-17, 2023. |
|---|
|
|
S3-2. It is ... from the situation of current situation and problem - drugstore of the electronic prescription 堀越博一 Journal of Japanese Society of Pharmaceutical Oncology 30: 18-18, 2023. |
|---|
|
|
S3-3. It is ... from the situation of current situation and problem - electronic medical chart vendor of the electronic prescription 岩津聖二 Journal of Japanese Society of Pharmaceutical Oncology 30: 19-19, 2023. |
|---|
|
|
S3-4. It is ... from the situation of problem of the electronic prescription and expectation - drugstore system vendor to the future 下坪信夫 Journal of Japanese Society of Pharmaceutical Oncology 30: 20-20, 2023. |
|---|
|
|
A pharmacist can do it for survivor ship realization of cancer survivor ship reconsideration ... most good luck 牧野あずみ, 高原悠子, 佐野元彦 Journal of Japanese Society of Pharmaceutical Oncology 30: 21-21, 2023. |
|---|
|
|
S4-1. About the role of pharmacist break walking cancer survivor ship outline - cancer journey together - 高橋都 Journal of Japanese Society of Pharmaceutical Oncology 30: 22-22, 2023. |
|---|
|
|
S4-2. The survivor ship support that hospital pharmacist practices 高原悠子 Journal of Japanese Society of Pharmaceutical Oncology 30: 23-23, 2023. |
|---|
|
|
S4-3. The survivor ship support that a drugstore pharmacist practices 石原千春 Journal of Japanese Society of Pharmaceutical Oncology 30: 24-24, 2023. |
|---|
|
|
S4-4. Now is the time, Survivorship! - What the patient wants from the pharmacist - 桜井なおみ Journal of Japanese Society of Pharmaceutical Oncology 30: 25-25, 2023. |
|---|
|
|
Skill of the team management and the pharmacist necessary for a pharmacist outpatient for the oral anticancer medicine 吉村知哲, 松尾宏一 Journal of Japanese Society of Pharmaceutical Oncology 30: 26-26, 2023. |
|---|
|
|
S5-1. Why does the oral anticancer medicine need the team management? 川上和宜 Journal of Japanese Society of Pharmaceutical Oncology 30: 27-27, 2023. |
|---|
|
|
S5-2. When pharmacist ambulatory service is painful strictly, we will leave result for a form 藤堂真紀 Journal of Japanese Society of Pharmaceutical Oncology 30: 28-28, 2023. |
|---|
|
|
S5-3. Skill of the pharmacist necessary for improvement in medication adherence 郷真貴子 Journal of Japanese Society of Pharmaceutical Oncology 30: 29-29, 2023. |
|---|
|
|
S5-4. Approach of the pharmacist making the side effect management be successful 組橋由記 Journal of Japanese Society of Pharmaceutical Oncology 30: 30-30, 2023. |
|---|
|
|
Now for the total support of patients with cancer the power of the pharmacist! ! ... which thinks about the intervention of the pharmacist in ... cancer pain relief 小澤有輝, 阿部健太郎 Journal of Japanese Society of Pharmaceutical Oncology 30: 31-31, 2023. |
|---|
|
|
S6-1. Tips about the pain-killer for cancer pain treatment to be provided effectively 小澤有輝 Journal of Japanese Society of Pharmaceutical Oncology 30: 32-32, 2023. |
|---|
|
|
S6-2. Art of the pain assessment snuggling up to patients 伊東俊雅 Journal of Japanese Society of Pharmaceutical Oncology 30: 33-33, 2023. |
|---|
|
|
S6-3. Do it nonpharmacologic therapy of the cancer pain and care ... Look before you leap; and ... 阿部健太郎 Journal of Japanese Society of Pharmaceutical Oncology 30: 34-34, 2023. |
|---|
|
|
S6-4. Pain intervention example in the outpatient 佐伯朋哉 Journal of Japanese Society of Pharmaceutical Oncology 30: 35-35, 2023. |
|---|
|
|
S6-5. Pain intervention example in the home care patient 餅原弘樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 36-36, 2023. |
|---|
|
|
Get started with mouth monitoring - Oral care necessary for cancer patients - 米良千春, 林稔展, 山口俊司 Journal of Japanese Society of Pharmaceutical Oncology 30: 37-37, 2023. |
|---|
|
|
S7-1. Basic knowledge of the oral mucosa 井村英人 Journal of Japanese Society of Pharmaceutical Oncology 30: 38-38, 2023. |
|---|
|
|
S7-2. ... which supports ... cancer treatment from oral cavity about the oral health care to the cancer medical therapy patients that a dental hygienist in After Covid-19 gives 池上由美子 Journal of Japanese Society of Pharmaceutical Oncology 30: 39-39, 2023. |
|---|
|
|
S7-3. We can do it as efforts - pharmacist for the mouth care of cancer chemotherapy patients 吉田謙介 Journal of Japanese Society of Pharmaceutical Oncology 30: 40-40, 2023. |
|---|
|
|
S7-4. Patients support ... that there is the health insurance pharmacy that we saw through ... mouth care to live with "a cancer" 米良千春 Journal of Japanese Society of Pharmaceutical Oncology 30: 41-41, 2023. |
|---|
|
|
Cancer drug therapy supported by the community - Thinking about the education of cancer pharmacotherapy for the next generation of pharmacists in Aichi - 鈴木大介, 宮崎雅之, 三星勇輝 Journal of Japanese Society of Pharmaceutical Oncology 30: 42-42, 2023. |
|---|
|
|
S8-1. Current situation and problem ... face of the medicine medicine cooperation of Okazaki-shi are ... for acquaintance to be able to see 村井宏通 Journal of Japanese Society of Pharmaceutical Oncology 30: 43-43, 2023. |
|---|
|
|
S8-2. The efforts as the specialized medical institution cooperation drugstore and future problem 鈴木大介 Journal of Japanese Society of Pharmaceutical Oncology 30: 44-44, 2023. |
|---|
|
|
S8-3. It is ... after the making of "the tool that a side effect is removed" education and duties support ... "gastrointestinal carcinoma Reference book" to a pharmacist engaged in cancer chemotherapy 小杉菜々子1,2), 石塚眞帆2), 岩間弓奈2), 加藤皐紀2), 北村葵2), 嶋洋将2), 末松菜月2), 鈴木大介2), 高木麻衣2), 高村京香2), 當麻丹香2), 西山貴章2), 松岡あゆみ2), 三星勇輝2), 村山遥香2), 村山三佳2), 山田卓摩2), 川合甲祐2), 田中章郎1), 宮崎雅之2) Journal of Japanese Society of Pharmaceutical Oncology 30: 45-45, 2023. |
|---|
|
|
S8-4. About the workshop plan of a hospital and the health insurance pharmacy in Aichi thinking about the medical cooperation that a pharmacist builds 杉山純子, 片山広美, 小島昌代, 地引勝, 星野有吾, 松岡あゆみ, 鷲野友亮, 岩田智樹, 宮崎雅之 Journal of Japanese Society of Pharmaceutical Oncology 30: 46-46, 2023. |
|---|
|
|
Being able to do it through irAE measures - community medical care cooperation in the pharmacist glance, it is assumed 湊川紘子, 川澄賢司, 吉野真樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 47-47, 2023. |
|---|
|
|
S9-1. Update of irAE management 吉野真樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 48-48, 2023. |
|---|
|
|
S9-2. The irAE manual which matches the glance of the health insurance pharmacy with a hospital, and binds an area together 鈴木貴之1), 鈴木栄2), 新井隆広3), 国吉央城4), 武井大輔1), 中山季昭1), 佐野元彦5) Journal of Japanese Society of Pharmaceutical Oncology 30: 49-49, 2023. |
|---|
|
|
S9-3. It is intervention and a mission to irAE of the insurance pharmacist in the line at a point 田中智枝 Journal of Japanese Society of Pharmaceutical Oncology 30: 50-50, 2023. |
|---|
|
|
S9-4. To be able to connect to the early detection of irAE; good use of ... outpatient department chemotherapy hot line ... 岩本義弘 Journal of Japanese Society of Pharmaceutical Oncology 30: 51-51, 2023. |
|---|
|
|
S9-5. Patient monitoring ... utilizing weapon - ePRO of the new irAE management 桂英之 Journal of Japanese Society of Pharmaceutical Oncology 30: 52-52, 2023. |
|---|
|
|
Support "bitterness" of the care ... patients of the psyche which a pharmacist carries how; or ... 田中康裕, 佐伯朋哉 Journal of Japanese Society of Pharmaceutical Oncology 30: 53-53, 2023. |
|---|
|
|
S10-1. To take "bitterness" of patients? It is ... from the viewpoint of ... pharmacist 原田寿 Journal of Japanese Society of Pharmaceutical Oncology 30: 54-54, 2023. |
|---|
|
|
S10-2. To understand anger ... psycho status of patient of patients with cancer, and to cope appropriately 清水研 Journal of Japanese Society of Pharmaceutical Oncology 30: 55-55, 2023. |
|---|
|
|
S10-3. With the psychology turn of eventss of viewpoint ... patients of the master of clinical phycologist/official recognition psychology and a correspondence method 武村尊生 Journal of Japanese Society of Pharmaceutical Oncology 30: 56-56, 2023. |
|---|
|
|
Tips, tricks and traps of pharmacist clinical studies 野村久祥, 辻大樹, 今給黎明彦 Journal of Japanese Society of Pharmaceutical Oncology 30: 57-57, 2023. |
|---|
|
|
S11-1. Join a story together; is clinical studies from tomorrow 武井大輔 Journal of Japanese Society of Pharmaceutical Oncology 30: 58-58, 2023. |
|---|
|
|
S11-2. It is ... for a case by wall at clinical studies enforcement and art - retrospective study to get over 横川貴志 Journal of Japanese Society of Pharmaceutical Oncology 30: 59-59, 2023. |
|---|
|
|
S11-3. Dispatch ... problem and precaution ... which you should work on of the evidence from a drugstore pharmacist 月岡良太 Journal of Japanese Society of Pharmaceutical Oncology 30: 60-60, 2023. |
|---|
|
|
S11-4. Stand on the progress of the whole area study of - present continuous that an involution power at clinical studies enforcement controls the quality of the study; and - 石塚友一 Journal of Japanese Society of Pharmaceutical Oncology 30: 61-61, 2023. |
|---|
|
|
S11-5. "What's the point of that survey you made?" Let's conduct a Kaizen-oriented questionnaire survey! 濃沼政美 Journal of Japanese Society of Pharmaceutical Oncology 30: 62-62, 2023. |
|---|
|
|
To aim at the family pharmacist, drugstore which snuggled up to patients with cancer; utilization ... of - "duties guidance about the cancer medical therapy of the family pharmacist, drugstore" 伊藤剛貴, 大塚昌孝, 高山俊輔 Journal of Japanese Society of Pharmaceutical Oncology 30: 63-63, 2023. |
|---|
|
|
S12-1. About making and an outline of the guidance 伊藤剛貴1,12), 下村直樹2,12), 金澤裕子3,12), 立澤明4,12), 坪田留央依5,12), 樋口昇大6,12), 文靖子7,12), 本田雅志8,12), 和田敦9,12), 高山俊輔10,12), 大塚昌孝11,12) Journal of Japanese Society of Pharmaceutical Oncology 30: 64-64, 2023. |
|---|
|
|
S12-2. To effectively utilize guidance; from the situation of the drugstore 下村直樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 65-65, 2023. |
|---|
|
|
S12-3. The effective example introduction that is described in guidance 本田雅志 Journal of Japanese Society of Pharmaceutical Oncology 30: 66-66, 2023. |
|---|
|
|
S12-4. "The collection of bonds of patients with cancer and the pharmacist" and term of Helen Keller 濃沼政美 Journal of Japanese Society of Pharmaceutical Oncology 30: 67-67, 2023. |
|---|
|
|
S12-5. Fix the eyes on future fine-view - specialty medical institution cooperation drugstore of the duties guidance; and ... 高山俊輔 Journal of Japanese Society of Pharmaceutical Oncology 30: 68-68, 2023. |
|---|
|
|
Let's think ... to instruction to snuggle up to patients with juvenile cancer together; of cancer reproductive medicine and the pharmacist is associated; ...! 小室雅人, 網野一真, 日置三紀 Journal of Japanese Society of Pharmaceutical Oncology 30: 69-69, 2023. |
|---|
|
|
S13-1. Intelligence and evaluation about the effect on generative function in cancer treatment 長谷川まゆみ Journal of Japanese Society of Pharmaceutical Oncology 30: 70-70, 2023. |
|---|
|
|
S13-2. Role of the pharmacist in a cancer, the reproductive medicine consultation support center 山崎香織 Journal of Japanese Society of Pharmaceutical Oncology 30: 71-71, 2023. |
|---|
|
|
S13-3. It is ... up to desired - youth cancer experience and fecundity to cancer reproductive medicine, a foster parent, special adoption 牧野かおり Journal of Japanese Society of Pharmaceutical Oncology 30: 72-72, 2023. |
|---|
|
|
What you should know that a pharmacist becomes the leading role and utilizes adverse event monitoring by ePRO & PRO-CTCAE by common practice 山口拓洋, 川口崇, 佐野元彦 Journal of Japanese Society of Pharmaceutical Oncology 30: 73-73, 2023. |
|---|
|
|
S14-1. ePRO utilization in clinical studies and the common practice to expect of a pharmacist 川口崇1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 74-74, 2023. |
|---|
|
|
S14-2. Expectation and problems in the introduction to common practice of ePRO 松波奈緒美 Journal of Japanese Society of Pharmaceutical Oncology 30: 75-75, 2023. |
|---|
|
|
S14-3. How does it support information obtained in ePRO? 臼井浩明 Journal of Japanese Society of Pharmaceutical Oncology 30: 76-76, 2023. |
|---|
|
|
S14-4. Merit ... of each Future Perspective - medical care person, patients in the ePRO utilization 鷲巣晋作 Journal of Japanese Society of Pharmaceutical Oncology 30: 77-77, 2023. |
|---|
|
|
S14-5. For inflection to common practice of ePRO, think from patients comment 金素安 Journal of Japanese Society of Pharmaceutical Oncology 30: 78-78, 2023. |
|---|
|
|
We have us for the smile of real - children of the childhood cancer medical therapy that a pharmacist snuggles up and supports 益子寛之, 湊川紘子 Journal of Japanese Society of Pharmaceutical Oncology 30: 79-79, 2023. |
|---|
|
|
S15-1. Cancer medical therapy of the pediatric domain 歌野智之 Journal of Japanese Society of Pharmaceutical Oncology 30: 80-80, 2023. |
|---|
|
|
S15-2. Of the supportive care of the childhood cancer domain, actually 戸津舞衣子 Journal of Japanese Society of Pharmaceutical Oncology 30: 81-81, 2023. |
|---|
|
|
S15-3. We think about the relation of the clinical pharmacist to support the children with cancer 日置三紀 Journal of Japanese Society of Pharmaceutical Oncology 30: 82-82, 2023. |
|---|
|
|
What can Onco-cardiology - pharmacist do? ... 井上裕貴, 玉木慎也 Journal of Japanese Society of Pharmaceutical Oncology 30: 83-83, 2023. |
|---|
|
|
S16-1. Expect it of tumor angiocardiology (Onco-Cardiology) outline pharmacist 向井幹夫1), 高木麻里2) Journal of Japanese Society of Pharmaceutical Oncology 30: 84-84, 2023. |
|---|
|
|
S16-2. Onco-cardiology to think about in a pharmacist viewpoint 根本真記 Journal of Japanese Society of Pharmaceutical Oncology 30: 85-85, 2023. |
|---|
|
|
S16-3. Pharmaceutical management of Onco-Cardiology to think about from the viewpoint of the circulatory organ 石田有希 Journal of Japanese Society of Pharmaceutical Oncology 30: 86-86, 2023. |
|---|
|
|
Promotion - of - hospital, a health insurance pharmacy, the drugstore pharmacist cooperation to support patients with cancer in an area 吉村知哲, 小原道子 Journal of Japanese Society of Pharmaceutical Oncology 30: 87-87, 2023. |
|---|
|
|
S17-1. Expectation to in connection with a role of the pharmacist in the area 小原道子 Journal of Japanese Society of Pharmaceutical Oncology 30: 88-88, 2023. |
|---|
|
|
S17-2. A relation and problem of the hospital pharmacist for patients with cancer 郷真貴子 Journal of Japanese Society of Pharmaceutical Oncology 30: 89-89, 2023. |
|---|
|
|
S17-3. Importance - of efforts - information sharing of the community medical care cooperation in the Gifu University Hospital outpatient department chemotherapy 廣瀬智恵美 Journal of Japanese Society of Pharmaceutical Oncology 30: 90-90, 2023. |
|---|
|
|
S17-4. Of a relation and the reporting to the team approach in medical care of the drugstore pharmacist, actually 大森智史 Journal of Japanese Society of Pharmaceutical Oncology 30: 91-91, 2023. |
|---|
|
|
S17-5. Patients support and information sharing by the drugstore pharmacist 友部賢 Journal of Japanese Society of Pharmaceutical Oncology 30: 92-92, 2023. |
|---|
|
|
With the local cancer support to support with an ALL pharmacist 長久保久仁子, 大野朋子 Journal of Japanese Society of Pharmaceutical Oncology 30: 93-93, 2023. |
|---|
|
|
S18-1. Cancer support in the area that a specialized medical institution cooperation drugstore takes 村田勇人 Journal of Japanese Society of Pharmaceutical Oncology 30: 94-94, 2023. |
|---|
|
|
S18-2. Responsibility and readiness ... which raise ... signboard thinking about the role of a certain authorized drugstore in an area 中島美紀 Journal of Japanese Society of Pharmaceutical Oncology 30: 95-95, 2023. |
|---|
|
|
S18-3. If patients with dementia have a diagnosis of a malignant tumor; is ... based on ... at-home on-site experience 大野朋子 Journal of Japanese Society of Pharmaceutical Oncology 30: 96-96, 2023. |
|---|
|
|
S18-4. Living-in-; supporting; examine; from a viewpoint of relation ... treatment at home of the pharmacist - 大須賀悠子 Journal of Japanese Society of Pharmaceutical Oncology 30: 97-97, 2023. |
|---|
|
|
Up-To-Date! Let's all protect the blood vessels of patients! Extravasation management associated with cancer drug therapy - Commemorative symposium on the publication of joint guidelines for extravasation associated with cancer drug therapy - 龍島靖明, 牧野好倫 Journal of Japanese Society of Pharmaceutical Oncology 30: 98-98, 2023. |
|---|
|
|
S19-1. Does the use of the Fosaprepitant influence EV risk? 相澤雄介 Journal of Japanese Society of Pharmaceutical Oncology 30: 99-99, 2023. |
|---|
|
|
S19-2. Are CQ steroid local site injection, the use of the drug for external use application recommended? 青山剛 Journal of Japanese Society of Pharmaceutical Oncology 30: 100-100, 2023. |
|---|
|
|
S19-3. Is the use of dexrazoxane recommended? 文靖子 Journal of Japanese Society of Pharmaceutical Oncology 30: 101-101, 2023. |
|---|
|
|
S19-4. Is cold compress, the hot compress recommended as local treatment to prevent aggravation, progression of dermatopathy, inflammation by EV? 菅野かおり Journal of Japanese Society of Pharmaceutical Oncology 30: 102-102, 2023. |
|---|
|
|
S19-5. About a drug and the interpretation added for a tissue disorder according to the drug-related classification newly 佐藤淳也 Journal of Japanese Society of Pharmaceutical Oncology 30: 103-103, 2023. |
|---|
|
|
New door of the cancer medical therapy that personalized medicine opens up 櫻井洋臣, 板垣麻衣, 米村雅人, 菊地正史 Journal of Japanese Society of Pharmaceutical Oncology 30: 104-104, 2023. |
|---|
|
|
S20-1. Basic knowledge of the examination for oncogene panel in the cancer genomic medicine 菊地正史1,2), 眞野成康1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 105-105, 2023. |
|---|
|
|
S20-2. Development and problem of the cancer medical therapy based on the examination for gene panel 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 30: 106-106, 2023. |
|---|
|
|
S20-3. New door of the cancer medical therapy that SCRUM-Japan works on 板垣麻衣 Journal of Japanese Society of Pharmaceutical Oncology 30: 107-107, 2023. |
|---|
|
|
The future of the community medical care cooperation that the cancer practice hospital cooperation training builds 三星勇輝, 野村充俊 Journal of Japanese Society of Pharmaceutical Oncology 30: 108-108, 2023. |
|---|
|
|
S21-1. As efforts ... institution accepting it primarily from the neighborhood drugstore of the training hospital in the cancer practice hospital cooperation training ... 野村充俊 Journal of Japanese Society of Pharmaceutical Oncology 30: 109-109, 2023. |
|---|
|
|
S21-2. It is ... mainly on the intern acceptance from efforts - distant place of the training hospital in the cancer practice hospital cooperation training 内山将伸 Journal of Japanese Society of Pharmaceutical Oncology 30: 110-110, 2023. |
|---|
|
|
S21-3. We experience the cancer practice hospital cooperation training and think about specialty. We become a pharmacist specialized in ... outpatient department cancer treatment 久田健登 Journal of Japanese Society of Pharmaceutical Oncology 30: 111-111, 2023. |
|---|
|
|
S21-4. The improvement of the pharmacist whom a cancer practice hospital cooperation training system brings in study awareness and the result 広池暁子 Journal of Japanese Society of Pharmaceutical Oncology 30: 112-112, 2023. |
|---|
|
|
S21-5. Efforts subsequent with having learned in the JASPO cancer practice hospital cooperation training 笛木景子 Journal of Japanese Society of Pharmaceutical Oncology 30: 113-113, 2023. |
|---|
|
|
What can a medical person do to draw patients power? Invitation ... to ... Patient Empowerment Program (PEP) 木本真司, 東光久 Journal of Japanese Society of Pharmaceutical Oncology 30: 114-114, 2023. |
|---|
|
|
S22-1. Only a thing, the pharmacist who can do it can do it to draw patients power because it is a pharmacist 渡邊裕之 Journal of Japanese Society of Pharmaceutical Oncology 30: 115-115, 2023. |
|---|
|
|
S22-2. To do Patient Empowerment Program (PEP) in "the life that it is prospective and grows for the patients X healthcare worker X PEP = patients, and there is" 村上明男 Journal of Japanese Society of Pharmaceutical Oncology 30: 116-116, 2023. |
|---|
|
|
Retching, vomiting measures of patients with cancer to think about in a drugstore, hospital pharmacist 青山剛, 松村敦子 Journal of Japanese Society of Pharmaceutical Oncology 30: 117-117, 2023. |
|---|
|
|
S23-1. Antiemesis measures in the cancer chemotherapy based on the latest evidence 飯原大稔 Journal of Japanese Society of Pharmaceutical Oncology 30: 118-118, 2023. |
|---|
|
|
S23-2. About the condition of a patient, a drug causing retching, vomiting 馬場勇太1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 119-119, 2023. |
|---|
|
|
S23-3. Intervention case to retching, vomiting of the drugstore pharmacist 松澤友里香 Journal of Japanese Society of Pharmaceutical Oncology 30: 120-120, 2023. |
|---|
|
|
S23-4. Unexpected formidable adversary - that case - team of colon cancer which suffered from control of retching in adjuvant chemotherapy after the operation met 飯村洋平 Journal of Japanese Society of Pharmaceutical Oncology 30: 121-121, 2023. |
|---|
|
|
Personal power, capacity for organization necessary to support patients with cancer 縄田修一, 大里洋一 Journal of Japanese Society of Pharmaceutical Oncology 30: 122-122, 2023. |
|---|
|
|
S24-1. Utilize importance - mind Fournet of the stress care of the medical person associating with patients with cancer; and ... 高宮有介 Journal of Japanese Society of Pharmaceutical Oncology 30: 123-123, 2023. |
|---|
|
|
S24-2. ... to think about in ... treatment at home to become the member of the multi-type of job team supporting patients with cancer, a family 大野朋子 Journal of Japanese Society of Pharmaceutical Oncology 30: 124-124, 2023. |
|---|
|
|
S24-3. We will get ready not to sprain the mind of ... person doing the best thinking about an evaluation method necessary for organizing to support a pharmacist 大里洋一 Journal of Japanese Society of Pharmaceutical Oncology 30: 125-125, 2023. |
|---|
|
|
S24-4. The way of the personal power and tissue by the large tissue 長沼未加 Journal of Japanese Society of Pharmaceutical Oncology 30: 126-126, 2023. |
|---|
|
|
2022 JASPO foreign countries training dispatch business report symposium 鈴木真也, 太田貴洋, 久松大祐 Journal of Japanese Society of Pharmaceutical Oncology 30: 127-127, 2023. |
|---|
|
|
S25-1. About the overseas training of JASPO 鈴木真也 Journal of Japanese Society of Pharmaceutical Oncology 30: 128-128, 2023. |
|---|
|
|
S25-2. On seeing the American medical system, we think about "cooperation" in Japanese ambulant treatment 越智美月 Journal of Japanese Society of Pharmaceutical Oncology 30: 129-129, 2023. |
|---|
|
|
S25-3. With the difference between Japan and American pharmacist system? Learn through ... foreign countries training, and how do want to make use in future; ... 田内淳子 Journal of Japanese Society of Pharmaceutical Oncology 30: 130-130, 2023. |
|---|
|
|
S25-4. What we participated in the overseas training as a health insurance pharmacy pharmacist and felt 山根孝太 Journal of Japanese Society of Pharmaceutical Oncology 30: 131-131, 2023. |
|---|
|
S25-5. Oncology Pharmacy at Memorial Sloan Kettering Cancer Center Lisa Modelevsky Journal of Japanese Society of Pharmaceutical Oncology 30: 132-132, 2023. |
|---|
|
|
S25-6. NCODA : Advancing Medically Integrated Oncology Around the Globe Tahsin Imam Journal of Japanese Society of Pharmaceutical Oncology 30: 133-133, 2023. |
|---|
|
|
S25-7. Expect it of a person of coming overseas training 太田貴洋 Journal of Japanese Society of Pharmaceutical Oncology 30: 134-134, 2023. |
|---|
|
|
S25-8. Advice to a person applying for a person of overseas training of the next fiscal year 本永正矩 Journal of Japanese Society of Pharmaceutical Oncology 30: 135-135, 2023. |
|---|
|
|
Basic seminar 1. Want a beginner to listen; is colon cancer treatment 高取俊和 Journal of Japanese Society of Pharmaceutical Oncology 30: 136-136, 2023. |
|---|
|
|
Basic seminar 2. Basic knowledge of the palliative care that a pharmacist wants to know 神林祐子 Journal of Japanese Society of Pharmaceutical Oncology 30: 137-137, 2023. |
|---|
|
|
Basic seminar 3. Basic knowledge of the lung cancer medical therapy 組橋由記 Journal of Japanese Society of Pharmaceutical Oncology 30: 138-138, 2023. |
|---|
|
|
Basic seminar 4. Pharmaceutical intervention in gastric cancer treatment 柿本秀樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 139-139, 2023. |
|---|
|
|
Basic seminar 5. Basics of the breast cancer medical therapy 宮本康敬 Journal of Japanese Society of Pharmaceutical Oncology 30: 140-140, 2023. |
|---|
|
|
Basic seminar 6. Chronic myelogenous leukemia 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 30: 141-141, 2023. |
|---|
|
|
O-1. The effect that closed system anesthesia drug transfusion system (chemosafe lock (TM) system) use gives for a cisplatin preparation 大橋邦央1), 樋口文子2), 衛藤智章2), 後藤隆2), 山下克也3), 清水裕彰2), 橋本雅司1) Journal of Japanese Society of Pharmaceutical Oncology 30: 142-142, 2023. |
|---|
|
|
O-2. Efforts to calculate cancer patient guidance and management fee C at cancer centers 山内紗綾香, 南のどか, 國東佑美, 大原沙織, 荒瀬みのり, 高橋知孝, 沼田範子, 上田里恵 Journal of Japanese Society of Pharmaceutical Oncology 30: 143-143, 2023. |
|---|
|
|
O-3. Examination of the long-term sterilitas condition in the multiple needle pad by the simulated vial aiming at the division preparation of the vial preparation 新田悠一朗1), 眞鍋貴行1,2), 松浦泰寛1), 仲谷彰規1), 石川良太1), 岩山訓典1,3), 神山直也1,2), 山本譲1), 中馬真幸1), 小野尚志1), 田崎嘉一1) Journal of Japanese Society of Pharmaceutical Oncology 30: 144-144, 2023. |
|---|
|
|
O-4. Attitude survey about the occupational exposure in the anticancer medicine administration management 鈴木寛人1,2), 徳本優喜3), 津曲恭一4) Journal of Japanese Society of Pharmaceutical Oncology 30: 145-145, 2023. |
|---|
|
|
O-5. Anticancer medicine pollution investigation in a nurse concerned with anticancer medicine administration and neighboring work environment 曾根裕美子1), 前田章光2), 加藤正孝1) Journal of Japanese Society of Pharmaceutical Oncology 30: 146-146, 2023. |
|---|
|
|
O-6. After completion of treatment with all anticancer agents utilizing PBPM about the construction of the hepatitis B reactivation measures in patients and an effective evaluation 鈴木雅人, 吉田弘樹, 安藤武志, 近藤舞子, 三屋良太, 牧原明秀, 高原悠子, 天野杏南, 鵜飼和宏, 今高多佳子, 木全司 Journal of Japanese Society of Pharmaceutical Oncology 30: 147-147, 2023. |
|---|
|
|
O-7. Fact-finding of the consultation contents to the foreign chemotherapy hot line in immune checkpoint inhibitor-treated patients 岩本義弘1), 馬見新佳那子1), 田中将貴1), 金子明日美1), 瀬戸裕美子1), 田内淳子1), 川澄賢司1), 中田佳代子2), 松井礼子1), 池田公史3), 川崎敏克1) Journal of Japanese Society of Pharmaceutical Oncology 30: 148-148, 2023. |
|---|
|
|
O-8. The effectiveness of the olanzapine combination antiemesis therapy for nausea, vomiting of patients with multiple myeloma to be given ASCT combination L-PAM massive dose therapy 加藤淳平1), 松本千明1), 立田真也1), 石田耕太1), 吉見猛1), 大林梨花2), 塚田信弘3), 石田禎夫3), 細谷治1) Journal of Japanese Society of Pharmaceutical Oncology 30: 149-149, 2023. |
|---|
|
|
O-9. Association between immune-mediated adverse event expression and nutritional index (PNI) in the checkpoint inhibitor monotherapy of immunity 古野龍也1), 橋本宇矩1), 松尾俊佑1), 白濱和加子1), 嘉村知子1), 細矢和久1), 江頭陽子1), 山下佳雄2), 井上卓也2), 山内盛泰2), 勝屋弘雄2), 野口満2), 荒金尚子2), 島ノ江千里1) Journal of Japanese Society of Pharmaceutical Oncology 30: 150-150, 2023. |
|---|
|
|
O-10. Examination of the usefulness of Serious ADR prediction tool CARG score in patients with old colon cancer 富士谷昌典, 木村初, 小泉祐一 Journal of Japanese Society of Pharmaceutical Oncology 30: 151-151, 2023. |
|---|
|
|
O-11. Genetic polymorphism analysis study on gemcitabine efficacy expression of patients with distant metastasis pancreatic cancer (GENESECT study) 矢野琢也1), 辻大樹2), 鈴木賢一3), 横川貴志4), 羽鳥正浩4), 川上和宜4), 中尾將彦5), 荒川雄一朗6), 松尾圭祐7), 大橋養賢8), 阪田安彦9), 小暮友毅10), 玉木慎也11), 和田敦12), 瀧祐介13), 新船怜2), 土屋莉花2), 石井浩14), 伊藤邦彦2), 福岡竜逸1) Journal of Japanese Society of Pharmaceutical Oncology 30: 152-152, 2023. |
|---|
|
|
O-12. A case in which crushed administration of Venetoclax tablets affected the increase in blood concentration 丸藤義翔1), 安武夫1,2), 城田幹夫2,3), 小林真之2,4) Journal of Japanese Society of Pharmaceutical Oncology 30: 153-153, 2023. |
|---|
|
|
O-13. Center between cross-sectional observational study - patients, pharmacists investigating difference in preference and concern between patients and healthcare workers for the metastatic renal-cell carcinoma medical treatment; and - 輪湖哲也1), 木村剛2), 藤井靖久3), 大澤崇宏4), 内富庸介5), 本多和典6), 大谷亜吏子7), 近藤美紀8), 光田吉秀9), 河合大輔9), 菅原道子9), 北野浩己9), 篠原信雄4) Journal of Japanese Society of Pharmaceutical Oncology 30: 154-154, 2023. |
|---|
|
|
O-14. We look at the rear about the side effect expression at the mirogabalin in patients with cancer and the pregabalin administration and weigh a mark 島谷良太1,2), 田中健太2,3), 田中怜2,4), 賀茂佳子2), 森本重輝2), 鴨志田武2), 原田翔平2), 石川寛2), 佐藤哲2), 篠道弘2), 田中大智1,2), 近藤美奈1), 高橋健二1), 高橋千惠子1) Journal of Japanese Society of Pharmaceutical Oncology 30: 155-155, 2023. |
|---|
|
|
O-15. Association between blood pressure control and dose intensity in the treatment early stage of the Lenvatinib for thyroid cancer 塩谷純子1), 正木千恵2), 杉野公則2), 寺澤友基子1), 横塚智1), 仲田三佐子1), 北川亘2), 伊藤公一2) Journal of Japanese Society of Pharmaceutical Oncology 30: 156-156, 2023. |
|---|
|
|
O-16. Effect on vital prognosis by the combination of stratification and proton pump inhibitor by the neutrophilic lymphocytes ratio of patients receiving immune checkpoint inhibitor 堀智貴1), 山本和宏3), 伊藤武文2), 生島繁樹1), 大村友博3), 矢野育子3) Journal of Japanese Society of Pharmaceutical Oncology 30: 157-157, 2023. |
|---|
|
|
O-17. Examination about the effect that proteinuria in the thyroid cancer Lenvatinib therapy gives for renal function 渋谷悠真, 鈴木真也, 榎田智弘, 岡野晋, 藤澤孝夫, 川崎敏克, 田原信 Journal of Japanese Society of Pharmaceutical Oncology 30: 158-158, 2023. |
|---|
|
|
O-18. The example that was carried out until follow after the administration from an injection anticancer agent preparation at a drugstore 飯盛弘康1), 山口健作1), 藤重健1), 鶴田展大2) Journal of Japanese Society of Pharmaceutical Oncology 30: 159-159, 2023. |
|---|
|
|
O-19. Hospital pharmacist questionary survey - duties burden about the efforts about the cooperation full addition of the foreign chemotherapy, side effect hearing, effect on drug instruction ... 齋藤一樹, 大坂紗也佳, 後藤慎平, 二瓶哲, 於本崇志, 長澤佳昭, 佐藤文彦, 工藤賢三 Journal of Japanese Society of Pharmaceutical Oncology 30: 160-160, 2023. |
|---|
|
|
O-20. About fact-finding of the pharmaceutical intervention for cancer treatment which a specialized medical institution cooperation drugstore conducted a year 本田雅志1), 原田素子1), 坂口敦彦1), 足立昇平1), 本村真悟1), 正木研1), 江淵愛1), 牧りえ1), 下川友香理2) Journal of Japanese Society of Pharmaceutical Oncology 30: 161-161, 2023. |
|---|
|
|
O-21. The evaluation of the onset of malignant tumor risk in patients with rheumatoid arthritis of the productive population: We look at the rear using the large-scale insurance claim information and examine a mark 豕瀬諒1), 中村有沙1), 大見里奈1), 岳野秀二郎2), 村木優一1) Journal of Japanese Society of Pharmaceutical Oncology 30: 162-162, 2023. |
|---|
|
|
O-22. The DVO (Drug Vial Optimization) introduction results for the understock of oil xanthan gum (R) 深田英嗣, 野々山雅俊, 坂上幸, 米山大輝, 山崎将英, 藤居賢, 福土将秀 Journal of Japanese Society of Pharmaceutical Oncology 30: 163-163, 2023. |
|---|
|
|
O-23. Consciousness change ... of intervention result - medical security, economic effect, nurse of the pharmacist to treatment with anticancer agent 上ノ段友里1), 伊藤智子2), 磯田祥1), 鈴木芳1), 富田珠美1), 矢野東和代2), 折田博之3) Journal of Japanese Society of Pharmaceutical Oncology 30: 164-164, 2023. |
|---|
|
|
O-24. About the making of information and the tool which are useful for the prevention and the treatment of cancer in patients and the family pharmacist 野村浩夫1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 165-165, 2023. |
|---|
|
|
O-25. Example that was given the lenograstim after the experience of filgrastim hypersensitivity 塚本名奈子1), 岩切悦子1), 辰己晃造1), 本田富得1), 平田建郎2), 竹内聖二3) Journal of Japanese Society of Pharmaceutical Oncology 30: 166-166, 2023. |
|---|
|
|
O-26. The case that was able to relieve a side effect of the antineoplastic by online medication counseling 洞口信貴1), 佐藤奈緒1), 花岡亞希1), 大場のぞみ1), 山田奈津美1), 伊藤和央2) Journal of Japanese Society of Pharmaceutical Oncology 30: 167-167, 2023. |
|---|
|
|
O-27. Example that examined optimum doses of the CBDCA+VP-16+Atezo therapy for patients with small cell lung cancer during haemodialysis 稲毛慶子1), 森裕也1), 溝口由梨香1), 伊藤光2), 藤本裕太郎2), 江原淳2), 則末泰博2), 枦秀樹1) Journal of Japanese Society of Pharmaceutical Oncology 30: 168-168, 2023. |
|---|
|
|
O-28. Multicenter retrospective study about the bevacizumab-related adverse event as the effect predictor of patients with first ovarian cancer 伊佐治麻里子1), 梅原健吾2), 神垣輝美3), 佐藤友昭4), 中嶋紘文5), 今野美里6), 畠山智明7) Journal of Japanese Society of Pharmaceutical Oncology 30: 169-169, 2023. |
|---|
|
|
O-29. The effect that the introduction of the administration method gives for retching, vomiting expression for bendamustine ten minutes 坂本靖宜, 長谷川拓也, 森谷拓海, 宇山佳奈, 清水絢子, 小森智也, 川邉桂, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 30: 170-170, 2023. |
|---|
|
|
O-30. Efforts to appropriate laboratory study enforcement at use of immune checkpoint inhibitor 永井大地1), 岡崎秀太1), 山本直輝2), 鎌田実3), 足立幸人4), 高橋一栄1) Journal of Japanese Society of Pharmaceutical Oncology 30: 171-171, 2023. |
|---|
|
|
O-31. Fact-finding about the weight assay date and the change of prescription in patients who received foreign cancer chemotherapy 中原紅葉1), 山口健太郎2), 橋本典也2), 古賀聖子2), 末廣真理恵1), 荻野清子2), 室高広1) Journal of Japanese Society of Pharmaceutical Oncology 30: 172-172, 2023. |
|---|
|
|
O-32. Effect of the HBV screening to patients who received cancer chemotherapy by the pharmacist using PBPM 東垂水郁圭, 喜田孝史, 坂遼, 辻田司, 安宅菜月, 熊谷康平, 木原理絵, 續木康夫 Journal of Japanese Society of Pharmaceutical Oncology 30: 173-173, 2023. |
|---|
|
|
O-33. Systematic exposure to unchanged drug excrement exposure to anticancer agent measures study using the 200 ppm hypochlorous acid water 伊東俊雅1,2), 山賀亮祐1,2), 中島美知穂1), 周治由香里1,2), 宇田将人1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 174-174, 2023. |
|---|
|
|
O-34. Contribution as a pharmacist to online medication guidance - Investigation of factors contributing to improvement of patient satisfaction - 2nd report 鈴木大介1), 吉川麻里子2), 中村佳代3), 藤井敦子1), 皆谷和弘4), 矢口いずみ1), 横山豊明1) Journal of Japanese Society of Pharmaceutical Oncology 30: 175-175, 2023. |
|---|
|
|
O-35. Cooperation with the dietitian using nourishment screening MUST in the foreign cancer chemotherapy 中川武史1), 木村律子2), 戸塚弘幸1), 高橋喜統1), 安本和生3), 政氏藤玄1) Journal of Japanese Society of Pharmaceutical Oncology 30: 176-176, 2023. |
|---|
|
|
O-36. Efforts toward the use of Trastuzumab Deruxtecan - Focusing on countermeasures against side effects in interstitial lung disease - 加藤貴由, 遠藤秀竜, 中島彩子, 見尾谷昇, 山崎崇 Journal of Japanese Society of Pharmaceutical Oncology 30: 177-177, 2023. |
|---|
|
|
O-37. In the foreign cancer chemotherapy patients follow-up, we share Q&A exchanged between a hospital, health insurance pharmacies 中村久美1), 鬼窪利英1), 佐藤遥2) Journal of Japanese Society of Pharmaceutical Oncology 30: 178-178, 2023. |
|---|
|
|
O-38. It is ... for evaluation - continuation-like enforcement of the foreign cancer medical treatment workshop for the local health insurance drugstore for medicine medicine cooperation reinforcement 宇留賀仁史1), 小井土啓一1), 山田みなみ1), 吉村航1), 堀田恵美子2), 松田悟郎3), 新藤学1) Journal of Japanese Society of Pharmaceutical Oncology 30: 179-179, 2023. |
|---|
|
|
O-39. Analysis of the factor that cannot calculate specific drug management instruction addition 2 to be able to see from the current situation of the medicine medicine cooperation in the cancer medical therapy 吉留実慧子1,16), 槙原克也2,16), 基村佳世2,16), 福井梨乃2,16), 野見山芳裕3,16), 山口恵4,16), 井上聖夜子5,16), 橋本一代6,16), 富永由美7,16), 喜田博美8,16), 奥澤文敏2,16), 西村香奈9,16), 平尾昴士9,16), 伊戸郷美10,16), 中野文仁11,16), 倉田由紀子12,16), 吉岡幸洋13,16), 大森由子14,16), 宮田憲一15,16) Journal of Japanese Society of Pharmaceutical Oncology 30: 180-180, 2023. |
|---|
|
|
O-40. Evaluation of the disease severity reduction effect by the PBPM introduction on hand-and-foot syndrome of the capecitabine 太田明秀, 北嶋利菜, 奥村美佑, 鍋城峻, 尾崎良輔, 大村侑平, 岡野翔, 重成大介, 中田浩雅 Journal of Japanese Society of Pharmaceutical Oncology 30: 181-181, 2023. |
|---|
|
|
O-41. Effectiveness and validity evaluation of "the irAE evaluation sheet" in the interview before checkpoint inhibitor administration by the nurse of immunity 吉田弘樹1), 柴田剛志2), 鈴木雅人1), 三屋良太1), 近藤舞子1), 牧原明秀1), 高原悠子1), 竹之内由紀3), 松浦美聡3), 木全司1) Journal of Japanese Society of Pharmaceutical Oncology 30: 182-182, 2023. |
|---|
|
|
O-42. Usefulness evaluation of the tracing report in the medicine medicine cooperation of our hospital 高崎修一1), 坂東拓哉1), 南ひさこ1), 須田範行1), 中島敬悦2), 横山さや香2), 中田佑太郎2), 佐藤みな2), 宇都宮弘典2), 萩原浩孝2), 長谷川遥2), 近藤真介3), 及川美紀3), 中山敬子3), 友本尭子3), 宇野博美3), 小林礼乃3), 中田丞4) Journal of Japanese Society of Pharmaceutical Oncology 30: 183-183, 2023. |
|---|
|
|
O-43. Current situation investigation ... multicenter questionary survey first report ... of cancer medicine medicine cooperation and specific drug management addition 2 in Osaka 喜田博美1,16), 槙原克也2,16), 基村佳世2,16), 福井梨乃2,16), 野見山芳裕3,16), 吉留実慧子4,16), 山口恵5,16), 井上聖夜子6,16), 橋本一代7,16), 富永由美8,16), 奥澤文敏2,16), 西村香奈9,16), 平尾昴士9,16), 井戸郷美10,16), 中野文仁11,16), 倉田由紀子12,16), 吉岡幸洋13,16), 大森由子14,16), 宮田憲一15,16) Journal of Japanese Society of Pharmaceutical Oncology 30: 184-184, 2023. |
|---|
|
|
O-44. Questionary survey about the usefulness of the illness medicine cooperation that the foreign cancer chemotherapy cooperation full addition results in 中込梢1), 稲野寛1), 香取祐介1), 佐々木寿子1), 田村和敬1), 八柳千春2), 佐々木治一郎3), 尾鳥勝也1,4) Journal of Japanese Society of Pharmaceutical Oncology 30: 185-185, 2023. |
|---|
|
|
O-45. One case that an adverse event occurred by combination of imatinib and parsley celery 吉田啓太郎1), 松崎由佳1), 西園直子1), 永崎一樹1), 落合晋介2) Journal of Japanese Society of Pharmaceutical Oncology 30: 186-186, 2023. |
|---|
|
|
O-46. The case that became CR after nivolumab administration of the third treatment for patients with AFP-producing recurrent stomach cancer 吉田勝好1), 安木早紀1), 田原明子1), 篠原由美2), 服部晋司3), 郷原学1) Journal of Japanese Society of Pharmaceutical Oncology 30: 187-187, 2023. |
|---|
|
|
O-47. One patient who evaded a prescription cascade by suggesting the appropriate supportive care for foreign cancer medical treatment patients 足立昇平1), 長澤陽2) Journal of Japanese Society of Pharmaceutical Oncology 30: 188-188, 2023. |
|---|
|
|
O-48. The example that intervened in primary treatment of colon cancer, the second treatment, patients receiving the third treatment by a telephone follow-up 下村翔一 Journal of Japanese Society of Pharmaceutical Oncology 30: 189-189, 2023. |
|---|
|
|
O-49. Have an examination for FoundationOne CDx evidence of PIK3CA mutation during duodenal Vater's papilla treatment for cancer, as a neuroendocrine system cancer an example received the Everolimus 青木洸英1), 佐々木茂樹1), 金井詩織1), 降旗誠2), 中村康平3), 杉田和夫1) Journal of Japanese Society of Pharmaceutical Oncology 30: 190-190, 2023. |
|---|
|
|
O-50. Fact-finding of the nivolumab + ipilimumab combination therapy in our hospital 濱武清範1), 小西史子1), 野間敏也1), 松田ちひろ1), 福井美礼1), 仲忠士1), 美和孝之1), 小島一晃1), 北英夫2) Journal of Japanese Society of Pharmaceutical Oncology 30: 191-191, 2023. |
|---|
|
|
O-51. About the results of use of enfortumab vedotin in our hospital and the occurrence of side effects, etc. 田中亜弥1), 衛藤智章1), 高崎紘臣2), 後藤隆1), 清水裕彰1) Journal of Japanese Society of Pharmaceutical Oncology 30: 192-192, 2023. |
|---|
|
|
O-52. Search of the index to evaluate the continuous follow-up of foreign cancer-treated patients 丸田勇樹1,2), 菊池俊裕1), 酒井理恵1), 中西正人1) Journal of Japanese Society of Pharmaceutical Oncology 30: 193-193, 2023. |
|---|
|
|
O-53. Usefulness of the case conference between drugstore - hospital in cancer chemotherapy patients 徳留雄太1), 野本敦文1), 武井優輝1), 笹川永里子1), 新井理沙1), 川島瑞生1), 三宅優子1), 土屋雅勇1), 光永義治1), 大熊祐美3), 森平彩友美3), 河村剛至1,2), 渡部多真紀1,2), 安野伸浩1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 194-194, 2023. |
|---|
|
|
O-54. Having been able to see it from the analysis of the tracing report in the specialized medical institution cooperation drugstore 吉田達司1), 藤田あゆみ2), 矢部和昭1), 杉浦伸哉2,3), 小原道子3), 串田一樹4) Journal of Japanese Society of Pharmaceutical Oncology 30: 195-195, 2023. |
|---|
|
|
O-55. Efforts of the medicine medicine cooperation in local basic hospital pharmacy and the Tsuchiura district that collaborated 堀越建一1,2), 金澤幸江1), 飯田遼3), 望月暁3), 猪瀬成史3) Journal of Japanese Society of Pharmaceutical Oncology 30: 196-196, 2023. |
|---|
|
|
O-56. Efforts of the medicine medicine cooperation in the Tsuchiura district that collaborated with local pharmacist society 飯田遼1), 玉田広明1), 仲野美樹1), 白井真理子1), 望月暁1), 安藤寛子1), 猪瀬成史1), 堀越建一2,3), 金澤幸江3), 椿浩之1) Journal of Japanese Society of Pharmaceutical Oncology 30: 197-197, 2023. |
|---|
|
|
O-57. The effect that reporting from hospital pharmacist through "information sharing paper" gives for the prescription suggestion by the drugstore pharmacist: We look at the rear and examine a mark 竹本将士1), 近藤勝弘1), 外海友規1), 手崎世織1), 後藤佳奈1), 中村大学1), 大橋一輝1), 菱谷まどか1), 日比陽子1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 198-198, 2023. |
|---|
|
|
O-58. How much can contribute to improvement in evaluation - knowledge of the online training for the local health insurance drugstore? ... 小井土啓一, 宇留賀仁史, 山田みなみ, 吉村航, 新藤学 Journal of Japanese Society of Pharmaceutical Oncology 30: 199-199, 2023. |
|---|
|
|
O-59. Examination of the effect on breast cancer perioperative treatment by COVID-19 infection change of outbreak 馬場楓1), 川元愛実1), 馬見新佳那子1), 植松真生2), 清原光2), 廣田玲2), 高橋信行2), 福田美佐緒2), 楠原正太2), 中島裕理2,3), 船坂知華子2,3), 仲尾岳大2,3), 近藤千紘2), 原野謙一2,3), 松原伸晃2), 内藤陽一2,3,4), 細野亜古2,5), 川崎敏克1), 向原徹2) Journal of Japanese Society of Pharmaceutical Oncology 30: 200-200, 2023. |
|---|
|
|
O-60. Comparison between modified FOLFIRINOX and tolerability of nal-IRI/FL in the second treatment of the unresectable progress recurrence pancreatic cancer 掛布優樹, 南島拓矢, 石田友規, 河野紀子, 宮崎雅之, 宮川泰宏, 溝口博之, 山田清文 Journal of Japanese Society of Pharmaceutical Oncology 30: 201-201, 2023. |
|---|
|
|
O-61. The blood level change of the sunitinib in metastatic nephrocyte cancer sunitinib chronic administration patients and the each metabolite and relations of the adverse event 里美貴1), 八島秀明2), 荒木拓也2), 森田順3), 大林真幸1), 神山紀子1), 小川良雄3), 深貝隆志3), 山本康次郎2), 向後麻里1) Journal of Japanese Society of Pharmaceutical Oncology 30: 202-202, 2023. |
|---|
|
|
O-62. Examination about the effect that trifluridine/Tipiracil and weight loss at the initial administration in the bevacizumab combination therapy give to onset of serious neutropenia 梅原健吾1), 高田慎也1), 山岸佳代1), 平川昌宏2), 藤川幸司2), 佐川保2), 佐藤秀紀3), 美濃興三1) Journal of Japanese Society of Pharmaceutical Oncology 30: 203-203, 2023. |
|---|
|
|
O-63. The case that was able to support emergency of cancer-treated patients foreign the relation of the family pharmacist 仲谷誠司 Journal of Japanese Society of Pharmaceutical Oncology 30: 204-204, 2023. |
|---|
|
|
O-64. A case of intervention using OTC for xerostomia caused by Selpercatinib 川崎祐介, 吉田神奈 Journal of Japanese Society of Pharmaceutical Oncology 30: 205-205, 2023. |
|---|
|
|
O-65. The effect that anticancer agent Drug vial optimization gives to medical expenses reduction 越智良明, 神尾良, 石黒真奈美, 河合典子, 石井弘幸 Journal of Japanese Society of Pharmaceutical Oncology 30: 206-206, 2023. |
|---|
|
|
O-66. We look at the rear about the usefulness of the hydrocortisone prophylaxis for the oxaliplatin hypersensitivity reaction and study a mark 田中万穂1), 小室雅人1), 小島康志2), 大橋養賢1), 増田純一1), 西村富啓1) Journal of Japanese Society of Pharmaceutical Oncology 30: 207-207, 2023. |
|---|
|
|
O-67. Investigation of usage status and adverse events of Trastuzumab Deruxtecan in patients with HER2-positive gastric cancer in our hospital 橋口麻依子, 久松大祐, 後藤隆, 清水裕彰 Journal of Japanese Society of Pharmaceutical Oncology 30: 208-208, 2023. |
|---|
|
|
O-68. Examination of the difference by the type of the anticancer medicine giving it to the injection site reaction expression in Fosaprepitant treated patients 基村佳世, 槙原克也, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 30: 209-209, 2023. |
|---|
|
|
O-69. The examination that Cryotherapy contributes to shortening for the hospitalization of the Melphalan massive dose therapy enforcement patients 野口果歩1), 金子憲太郎1), 川口文誉1), 杉本誠1), 豊田茂雄2), 小林路子1) Journal of Japanese Society of Pharmaceutical Oncology 30: 210-210, 2023. |
|---|
|
|
O-70. Glasgow Prognostic Score does not influence albumin conjugate paclitaxel-induced neuropathic frequencies 佐伯結衣, 橋詰淳哉, 長瀬青葉, 原澤仁美, 兒玉幸修, 大山要 Journal of Japanese Society of Pharmaceutical Oncology 30: 211-211, 2023. |
|---|
|
|
O-71. About the case that by conducting online telephone follow, discovered the side effect of the anticancer agent 木元孝至, 薮田貴哉 Journal of Japanese Society of Pharmaceutical Oncology 30: 212-212, 2023. |
|---|
|
|
O-72. Example that we were able to perform a satisfying follow-up to foreign cancer chemotherapy patients through cancer, blood disorder notebook application "Welby my clinical record ONC" 田中亜優実, 和田憲周, 林智子, 山本侑記, 藤井美和子 Journal of Japanese Society of Pharmaceutical Oncology 30: 213-213, 2023. |
|---|
|
|
O-73. We look at safety of the paclitaxel +S-1 combination therapy for unresectable progress, recurrent esophageal cancer and the rear about the effect of treatment and examine a mark 原伸輔1), 田中晃司2), 新谷拓也1), 廣部祥子1,3,4), 山本智也1), 奥田真弘1,4) Journal of Japanese Society of Pharmaceutical Oncology 30: 214-214, 2023. |
|---|
|
|
O-74. Expression and prognosis of the immune-mediated adverse event with the immune checkpoint inhibitor in gastric cancer third treatment 橋本雅之1), 松山仁2), 近藤裕志1), 平井あすか1), 村地康1), 田村雅子3), 中谷恭子3), 高垣佳史1) Journal of Japanese Society of Pharmaceutical Oncology 30: 215-215, 2023. |
|---|
|
|
O-75. We look at the rear about steroid sparing in the antiemesis therapy of weekly GEM+nabPTX regimen and examine a mark 相楽勇人1), 嵯峨千春2), 佐々木勇人3), 進藤吉明3), 田中雄一3) Journal of Japanese Society of Pharmaceutical Oncology 30: 216-216, 2023. |
|---|
|
|
O-76. Investigation about the effect that a change of the portable chronofuser in the 5-FU sustained administration gives to patients 中塚美穂, 樹下恵子, 西塔志織, 村松宏美, 稲田有里, 塚崎陽彦, 康至 Journal of Japanese Society of Pharmaceutical Oncology 30: 217-217, 2023. |
|---|
|
|
O-77. The examination of the prognostic factor after the peg filgrastim administration of patients who received DCF therapy before cancer of the esophagus technique: The effect that a neutropenia gives to effect of treatment after the operation 稲垣貴士1,2), 里美貴2), 金正興3), 大塚耕司4), 村上雅彦4), 向後麻里2) Journal of Japanese Society of Pharmaceutical Oncology 30: 218-218, 2023. |
|---|
|
|
O-78. Investigation of risk factors affecting survival time in patients with relapsed or refractory multiple myeloma after administration of the proteasome inhibitor Carfilzomib 萩原宏美1,2), 中山貴文3), 橋本大哉4), 楠本茂5), 福田英克4), 神谷武2,4), 飯田真介5) Journal of Japanese Society of Pharmaceutical Oncology 30: 219-219, 2023. |
|---|
|
|
O-79. Can the inflammatory response before the chemotherapy enforcement become the biomarker predicting neutropenia after the treatment? 白岩健, 衛藤大輝, 安部博宣, 田中遼大, 龍田涼祐, 伊東弘樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 220-220, 2023. |
|---|
|
|
P-001. Study of the risk factor of the onset of febrile neutropenia with the melphalan administration in patients with multiple myeloma 安田昌宏1,2,3), 舘知也1,2,3), 大澤友裕1), 藤井祥矢1), 井上誠二1), 渡邉久高1), 牧野哲平1), 長屋雄大1), 森田美穂1), 田中和秀1), 田中佑佳1), 青山智1), 寺町ひとみ3), 笠原千嗣2,4), 水井貴詞1) Journal of Japanese Society of Pharmaceutical Oncology 30: 221-221, 2023. |
|---|
|
|
P-002. Dexamethasone for the prevention of retching, vomiting with the induction therapy of acute myeloid leukemia, investigation about the effectiveness, the safety of aprepitant 清水悠太1), 南貴之1), 若月淳一郎1), 飯野昌樹2), 松本香織1), 小林義文1) Journal of Japanese Society of Pharmaceutical Oncology 30: 222-222, 2023. |
|---|
|
|
P-003. A comparison of the protective efficacy of diuretics one drug administration for the renal failure by the cisplatin and the two-drug administration and analysis of the risk factor of the onset of renal failure 高木彩香1), 林稔展1), 三好孝法2), 小泉陽奈子1), 津曲恭一3), 横田千明4), 中野貴文1), 松尾宏一1), 江川孝1) Journal of Japanese Society of Pharmaceutical Oncology 30: 223-223, 2023. |
|---|
|
|
P-004. The Abemaciclib prescription handling situation in the health insurance pharmacy 照屋千津子, 野々原育子, 土橋美和 Journal of Japanese Society of Pharmaceutical Oncology 30: 224-224, 2023. |
|---|
|
|
P-005. The intervention situation of a glycemic control method and the pharmacist by the diabetologist at the cancer medical therapy 石田翔1), 水木一仁2), 白木政博1), 松本俊治1) Journal of Japanese Society of Pharmaceutical Oncology 30: 225-225, 2023. |
|---|
|
|
P-006. The enforcement situation investigation of the cisplatin gemcitabine Necitumumab combination therapy for the squamous cell carcinoma of lung 衛藤智章, 松木奈緒子, 久松大祐, 清水裕彰 Journal of Japanese Society of Pharmaceutical Oncology 30: 226-226, 2023. |
|---|
|
|
P-007. About the intervention of the pharmacist to the examination of the patients receiving immune checkpoint inhibitor order 江原美里1), 畑裕基2), 山本友佳子2), 宮城和代2), 山下大輔2), 井上敦介3), 吉野宗宏2), 福田利明1) Journal of Japanese Society of Pharmaceutical Oncology 30: 227-227, 2023. |
|---|
|
|
P-008. Usefulness of the pharmaceutical management by the exclusive duty pharmacist placement to a foreign chemotherapy room 山口亜由美 Journal of Japanese Society of Pharmaceutical Oncology 30: 228-228, 2023. |
|---|
|
|
P-009. Evaluation of the usefulness of Prognostic Nutritional Index as the immune-mediated adverse event expression predictor in patients with non-small cell lung cancer 三好孝法1), 宮下裕央2), 深澤真実1), 和佐野英子1), 花田聖典1), 大橋邦央1), 橋本雅司1) Journal of Japanese Society of Pharmaceutical Oncology 30: 229-229, 2023. |
|---|
|
|
P-010. Effective and safe comparison of filgrastim BS note syringe "F" (R) and the noy fatty tuna gin (R) note in the neutropenia with the chemotherapy 遠藤晋吾1), 藤井一美1), 安井友佳子2), 石坂敏彦2) Journal of Japanese Society of Pharmaceutical Oncology 30: 230-230, 2023. |
|---|
|
|
P-011. Adherence investigation of the oral anticancer medicine which is susceptible to the diet 沼崎香, 鯨明美, 小野恵美子, 丹羽直人 Journal of Japanese Society of Pharmaceutical Oncology 30: 231-231, 2023. |
|---|
|
|
P-012. Examination about the expression situation and the risk factor of peripheral neuropathy in patients who received paclitaxel 城口将太, 荒木諒, 坂林加奈子, 吉川英里, 麻生美佐子 Journal of Japanese Society of Pharmaceutical Oncology 30: 232-232, 2023. |
|---|
|
|
P-013. Comparison of loxoprofen and acetaminophen in the infusion reaction prevention with rituximab 山中雄平, 高橋正也, 中村安孝 Journal of Japanese Society of Pharmaceutical Oncology 30: 233-233, 2023. |
|---|
|
|
P-014. The expression situation and correspondence of the diarrhea at the Abemaciclib administration for the metastasis, recurrent breast cancer case 石原泰子1), 石田亮2), 鶴海宏之4), 西宮祐輔5), 西村健二1), 亀井健人1), 赤木晋介1), 徳田衡紀1), 上野彩子3), 山口和盛3), 高柳和伸1) Journal of Japanese Society of Pharmaceutical Oncology 30: 234-234, 2023. |
|---|
|
|
P-015. Investigation about the onset of side effect situation of nivolumab once 240mg2 week distance alone and once 480mg4 week distance alone in the Gifu comprehensive medical care center 伊藤健史, 高瀬彩奈, 安江諒平, 眞野翔太, 田中佳子, 井上壽江, 平下智之 Journal of Japanese Society of Pharmaceutical Oncology 30: 235-235, 2023. |
|---|
|
|
P-016. The cancer interspecies side effect of Cabozantinib expression situation investigation 津幡あつ実, 角川幸男, 清水克次, 竹田健志, 井上聡子, 高木麻里 Journal of Japanese Society of Pharmaceutical Oncology 30: 236-236, 2023. |
|---|
|
|
P-017. Investigation of the immune-mediated adverse event and examination situation with the immune checkpoint inhibitor in our hospital 遠藤一江, 斉藤美香 Journal of Japanese Society of Pharmaceutical Oncology 30: 237-237, 2023. |
|---|
|
|
P-018. Correlative analysis of a UGT1A1 heterozygote gene and the effect of treatment in patients with unresectable pancreatic cancer which introduced mFOLFIRINOX therapy into initial chemotherapy 南雲昭人1), 田中怜2,3), 宮口貴守2), 賀茂佳子2), 鴨志田武2), 石川寛2), 篠道弘2) Journal of Japanese Society of Pharmaceutical Oncology 30: 238-238, 2023. |
|---|
|
|
P-019. Investigation of the understanding degree of patients in the medication support using the video and the satisfaction 廣瀬知子1), 荻原智子1), 河野未央1), 堤千寿子2), 井上謙一3), 土井卓子3) Journal of Japanese Society of Pharmaceutical Oncology 30: 239-239, 2023. |
|---|
|
|
P-020. Exploratory examination of the adverse event onset of hepatocytes cancer risk factor in the Atezolizumab + bevacizumab therapy 河原陽介, 堀合拓貴, 水野奈穂子, 加藤良治 Journal of Japanese Society of Pharmaceutical Oncology 30: 240-240, 2023. |
|---|
|
|
P-021. Can put it in the Gifu Red Cross hospital; and the situation of the next anticancer medicine internal use instruction and the evaluation 石原祥史, 岡健太郎, 松本智史, 木村繁和, 林貴子 Journal of Japanese Society of Pharmaceutical Oncology 30: 241-241, 2023. |
|---|
|
|
P-022. Look at the rear about the expression of immune-mediated adverse event (irAE) situation with the Pembrolizumab administration; mark investigation 田内明佳 Journal of Japanese Society of Pharmaceutical Oncology 30: 242-242, 2023. |
|---|
|
|
P-023. Investigation of the side effect of difference in calculation method expression of Carboplatin situation 濱野麻子, 三角紳博 Journal of Japanese Society of Pharmaceutical Oncology 30: 243-243, 2023. |
|---|
|
|
P-024. Investigation about the Nivolumab + Ipilimumab + chemotherapy combination therapy in the non-small cell lung cancer 大登剛, 土屋裕伴, 中里健志, 新井亘 Journal of Japanese Society of Pharmaceutical Oncology 30: 244-244, 2023. |
|---|
|
|
P-025. Investigation and consideration of the occurrence of administration site reactions in combination with Fosnetupitant in breast cancer EC therapy 堀田真由, 宮本義浩, 金子欧作, 宮本愛果, 野中明日香, 平出耕石 Journal of Japanese Society of Pharmaceutical Oncology 30: 245-245, 2023. |
|---|
|
|
P-026. A survey of the use of Venetoclax for acute myeloid leukemia in our hospital 桑崎綾子, 松下尚弘, 原友子, 野中敏治 Journal of Japanese Society of Pharmaceutical Oncology 30: 246-246, 2023. |
|---|
|
|
P-027. A comparative study of the efficacy of Fosnetupitant and Fosaprepitant in a single institution 松坂和正, 中山季昭, 安部智哉, 角坂惟生, 植木麻弥, 鈴木貴之, 武井大輔, 大塚公庸 Journal of Japanese Society of Pharmaceutical Oncology 30: 247-247, 2023. |
|---|
|
|
P-028. Efforts of the foreign instruction in the Abemaciclib remedy patients 赤松祐季, 南のどか, 國東佑美, 山内紗綾香, 大原沙織, 荒瀬みのり, 高橋知考, 沼田範子, 上田里恵 Journal of Japanese Society of Pharmaceutical Oncology 30: 248-248, 2023. |
|---|
|
|
P-029. Fact-finding of the hypomagnesemia by Panitumumab and examination of the risk factor 土屋裕伴1), 大村健二2), 新井亘1) Journal of Japanese Society of Pharmaceutical Oncology 30: 249-249, 2023. |
|---|
|
|
P-030. Investigation about the current situation of the antiemesis therapy in the childhood cancer chemotherapy 眞鍋綾, 濟川聡美, 山下登, 飛鷹範明, 田中守 Journal of Japanese Society of Pharmaceutical Oncology 30: 250-250, 2023. |
|---|
|
|
P-031. Examination of the effect that Lenvatinib initial dosage gives to a medication continuance rate on unresectable hepatocellular carcinoma 渡邉直優, 坂本靖宜, 井出和男, 川邉桂, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 30: 251-251, 2023. |
|---|
|
|
P-032. Operation of the pressure therapy for the purpose of the chemotherapy-induced peripheral neuropathy prevention in our hospital 霍間ひろの1), 箕輪智子2,5), 長谷川静江2,4), 佐藤大輔1), 岡田侑子1), 山室明子1), 池田美咲1), 窪田奈々1), 加藤菊郎1), 仁科晴弘3,5) Journal of Japanese Society of Pharmaceutical Oncology 30: 252-252, 2023. |
|---|
|
|
P-033. Examination about the infusion reaction frequencies of trastuzumab precedence biomedicine and the biofollowing article and the risk factor 伊賀久美, 山下登, 濟川聡美, 飛鷹範明, 田中守 Journal of Japanese Society of Pharmaceutical Oncology 30: 253-253, 2023. |
|---|
|
|
P-034. Effect of the Hangeshashinto for oral mucositis to develop in the patients who received cancer treatment in our hospital 中野悠馬, 品田似奈, 加藤水月, 関口朝美, 大野豊 Journal of Japanese Society of Pharmaceutical Oncology 30: 254-254, 2023. |
|---|
|
|
P-035. After the colon cancer technique using the capecitabine relative - single institution rearward investigation, interim report - of a surgical site and the onset in patients who received adjuvant chemotherapy of diarrhea 掛谷雅之1), 諸角一成2), 原賢康3), 三井章3), 佐藤由美子2) Journal of Japanese Society of Pharmaceutical Oncology 30: 255-255, 2023. |
|---|
|
|
P-036. Grasp of the onset of hypomagnesemia situation with the antiEGFR antibody administration for patients with colon cancer 住谷達也, 阿部多一, 林哲哉, 井口恵美子 Journal of Japanese Society of Pharmaceutical Oncology 30: 256-256, 2023. |
|---|
|
|
P-037. Fact-finding of the DOAC administration to cancer-related venous thromboembolism in our hospital 辻麻衣, 加賀麻友美, 赤羽根純, 細沼花穂里, 門田佳子 Journal of Japanese Society of Pharmaceutical Oncology 30: 257-257, 2023. |
|---|
|
|
P-038. Use investigation of the Atezolizumab + Bevacizumab therapy in our hospital and search of the side effect expression risk factor 山田早, 土屋裕伴, 国吉央城, 新井亘 Journal of Japanese Society of Pharmaceutical Oncology 30: 258-258, 2023. |
|---|
|
|
P-039. Usefulness of the peg filgrastim administration in the dose-dense EC therapy and safe evaluation 濱みゆき, 高田慎也, 山岸佳代, 美濃興三 Journal of Japanese Society of Pharmaceutical Oncology 30: 259-259, 2023. |
|---|
|
|
P-040. Inflection of PBPM in the Japanese Red Cross Society Nagasaki atomic bomb hospital outpatient department treatment room 原田周平 Journal of Japanese Society of Pharmaceutical Oncology 30: 260-260, 2023. |
|---|
|
|
P-041. It is analyzed the onset of vascular pain factor in the CapeOx therapy of the adjuvant chemotherapy after the colon cancer technique 石橋正祥1), 飯村洋平1), 古川直樹1), 流石智恵子1), 馬場啓介2), 朴成和2), 黒田誠一郎1) Journal of Japanese Society of Pharmaceutical Oncology 30: 261-261, 2023. |
|---|
|
|
P-042. The prescription situation investigation of the prophylactic gargle for chemotherapy-induced oral mucositis of the pyrimidine system regimen fluoride 山田将悟1,2), 藤林遼1), 朝倉幹己1), 田中耕太1), 菊地義明1), 高橋誠1), 田中正臣1), 鈴木夏子3), 佐藤隆司3) Journal of Japanese Society of Pharmaceutical Oncology 30: 262-262, 2023. |
|---|
|
|
P-043. Effect on prophylactic antiemesis therapy for digestive organ cancer chemotherapy patients having difficulty in dexamethasone preparation supply by COVID-19 大井田紗希, 新井聡子, 村上明男, 中野涼太, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 30: 263-263, 2023. |
|---|
|
|
P-044. We look at the multicenter rear about the blood toxicity by the Palbociclib weight loss start for the breast cancer and study a mark 鈴木訓史1), 和久井卓2), 小林美奈子1), 東敬太1), 内藤義博1) Journal of Japanese Society of Pharmaceutical Oncology 30: 264-264, 2023. |
|---|
|
|
P-045. Examination of the impaired renal function protective efficacy of the intravenous magnesium preparation in head and neck cancer chemoradiotherapy patients using the high-dose cisplatin 東山倫子1,2), 毛利順一1,2), 水藤稜平1), 尾鳥勝也1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 265-265, 2023. |
|---|
|
|
P-046. Questionary survey to confirm the usefulness of the telephone follow-up for patients treated in a cancer special hospital 下村直樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 266-266, 2023. |
|---|
|
|
P-047. Look at the single institution rear examining the use actual situation of the strong opioid analgesic for the oropharynx mucositis at the allogeneic hematopoietic stem cell transplantation; a mark observational study 竹内皓太1), 津野丈彦1), 山本環1), 山口智子1), 宮崎拓也2), 小杉三弥子1), 佐橋幸子1) Journal of Japanese Society of Pharmaceutical Oncology 30: 267-267, 2023. |
|---|
|
|
P-048. Prior examination at the irinotecan administration, investigation of side effect measures 前田美紀, 高木淳也, 加藤一郎, 生田和之, 海野祥生, 山本恵梨香 Journal of Japanese Society of Pharmaceutical Oncology 30: 268-268, 2023. |
|---|
|
|
P-049. Evaluation for safety of the daratumumab reduction of working hours administration and the economic aspect 生田和之1), 海野祥生1), 高木淳也1), 前田美紀1), 山本恵梨香1), 加藤一郎1), 藤田浩之2) Journal of Japanese Society of Pharmaceutical Oncology 30: 269-269, 2023. |
|---|
|
|
P-050. Safe examination of the bevacizumab administration that is the Biosimilar in patients with non-small cell lung cancer 初山多恵1), 松下拓夢2), 後藤桂輔1), 片岡優太1), 高橋連1), 岡崎泰香1), 荒木有希1), 原田直美1), 高力茂1), 若本あずさ1), 佐藤秀紀2) Journal of Japanese Society of Pharmaceutical Oncology 30: 270-270, 2023. |
|---|
|
|
P-051. The use actual situation of the herbal medicinal products in the chemotherapy enforcement patients of our hospital 鹿間友絵, 上原美佐, 生田和之, 海野祥生, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 30: 271-271, 2023. |
|---|
|
|
P-052. The renal function of the patients who received CAPOX therapy and relative examination of the adverse event expression 清水敦也1), 遠藤亮祐1), 中村拓海1), 佐藤秀紀3), 長谷川功1), 鶴間哲弘2) Journal of Japanese Society of Pharmaceutical Oncology 30: 272-272, 2023. |
|---|
|
|
P-053. The duties actual situation and attitude survey of the young pharmacist in our hospital cancer pharmacist outpatient department 山下亜由子, 岩倉弥生子, 武富瑞希, 本田梨紗, 中村佳菜, 合田明博 Journal of Japanese Society of Pharmaceutical Oncology 30: 273-273, 2023. |
|---|
|
|
P-054. Examination of the predictor of the pre-back using the peripheral blood data in the patients with non-small cell lung cancer and the immune-mediated adverse event 竹田あかね1), 井上裕貴1,2), 山本智子1), 吉田知由1), 北川智余恵2,3), 沖昌英4) Journal of Japanese Society of Pharmaceutical Oncology 30: 274-274, 2023. |
|---|
|
|
P-055. The use situation of olanzapine for CINV in patients with foreign cancer chemotherapy enforcement 波部未央佳, 大田晴香, 研真梨子, 田中将太, 前原大輔, 日生下美紀, 石田達彦 Journal of Japanese Society of Pharmaceutical Oncology 30: 275-275, 2023. |
|---|
|
|
P-056. announcer to patients with digestive organ cancer in our hospital leaks and examines it with an investigation about the use situation of phosphorus 久松大祐, 橋本未雷, 後藤隆, 清水裕彰 Journal of Japanese Society of Pharmaceutical Oncology 30: 276-276, 2023. |
|---|
|
|
P-057. Examination of the injection site reaction protective efficacy by the oxaliplatin-containing regimen using the infusion warming law 藤原未稀1), 牧賢利1), 高田遼1), 中山やちよ1), 角田和子2), 世良智子2), 横田志文2), 尾關真美2), 吹本和美2), 高田薫2), 岡田俊明3), 高橋洋子1), 田村浩二1) Journal of Japanese Society of Pharmaceutical Oncology 30: 277-277, 2023. |
|---|
|
|
P-058. Examination of the effectiveness of the nivolumab for the HER2-positive gastric cancer 小笠原健, 中居肇 Journal of Japanese Society of Pharmaceutical Oncology 30: 278-278, 2023. |
|---|
|
|
P-059. Investigation about the bevacizumab cancellation by the rise in protein in urine/creatinine ratio by the Atezolizumab bevacizumab combination therapy for the hepatocellular carcinoma 藤田強記1), 井上勝光2), 湊本康則2), 清水裕彰1) Journal of Japanese Society of Pharmaceutical Oncology 30: 279-279, 2023. |
|---|
|
|
P-060. Inspection (how you catch an appearance risk) of the need of weight loss, the discontinuation in the XELOX therapy (after the operation adjuvant chemotherapy) 相澤康子 Journal of Japanese Society of Pharmaceutical Oncology 30: 280-280, 2023. |
|---|
|
|
P-061. After the colon cancer technique judging from MSI test result in our hospital of the adjuvant chemotherapy, actually 橘尚子 Journal of Japanese Society of Pharmaceutical Oncology 30: 281-281, 2023. |
|---|
|
|
P-062. Exploratory study of the fruition factor of the nanoliposomal irinotecan-based chemotherapy after the irinotecan-based chemotherapy in patients with pancreatic cancer 山田紗由美1), 井上裕貴1,3), 水谷実花1), 竹田伸2), 吉田知由1), 末永雅也2), 片岡政人2) Journal of Japanese Society of Pharmaceutical Oncology 30: 282-282, 2023. |
|---|
|
|
P-063. The effect that sleep disorder before the chemotherapy start gives for retching, vomiting with the epirubicin cyclophosphamide therapy for patients with breast cancer 稲田佑亮, 京谷充崇, 山下敦志 Journal of Japanese Society of Pharmaceutical Oncology 30: 283-283, 2023. |
|---|
|
|
P-064. An effective use dose of the mirogabalin for chemotherapy-induced peripheral neuropathy and safe exploratory investigation 井上裕貴1,2), 安藤舞2), 白石和寛3), 杉山圭司3), 吉田知由2), 北川智余恵3) Journal of Japanese Society of Pharmaceutical Oncology 30: 284-284, 2023. |
|---|
|
|
P-065. Study on sarcopenia measurement significance after the operation before operation in patients with adjuvant chemotherapy enforcement colon cancer 川島健 Journal of Japanese Society of Pharmaceutical Oncology 30: 285-285, 2023. |
|---|
|
|
P-066. Prognosis of Lenvatinib using mALBI in the hepatocellular carcinoma and exploratory study on adverse event prediction 伊藤大輔 Journal of Japanese Society of Pharmaceutical Oncology 30: 286-286, 2023. |
|---|
|
|
P-067. The use situation of Abemaciclib tablets in our hospital 天野正康, 鈴木諒, 桑原健太, 三和知佳, 富田歩子 Journal of Japanese Society of Pharmaceutical Oncology 30: 287-287, 2023. |
|---|
|
|
P-068. A case where cancer chemotherapy could be continued due to Anamorelin marked effect 明石真弓1), 木村弓子1), 小村俊博2) Journal of Japanese Society of Pharmaceutical Oncology 30: 288-288, 2023. |
|---|
|
|
P-069. The case that a drugstore pharmacist was able to intervene in opioid gradual decrease and pain control 淺原洋介1), 坂本健太郎2), 石橋彩1), 赤岩亨1), 田中康照2), 岸本忠士1) Journal of Japanese Society of Pharmaceutical Oncology 30: 289-289, 2023. |
|---|
|
|
P-070. After Pembrolizumab administration, myositis merger myasthenia gravis develops early, is one of pulmonary multi-type cancer with suspected exacerbation by steroid 長瀬友樹1), 渡邉美月1), 阪本さくら1), 石岡美樹1), 多田裕司2), 篠崎浩司1) Journal of Japanese Society of Pharmaceutical Oncology 30: 290-290, 2023. |
|---|
|
|
P-071. One case that a drugstore pharmacist coped with to the lacrimation which developed in patients with colon cancer during capecitabine + bevacizumab therapy 鈴木万衣1), 藤田あゆみ2), 宇津木香奈1), 杉浦伸哉2) Journal of Japanese Society of Pharmaceutical Oncology 30: 291-291, 2023. |
|---|
|
|
P-072. One case of patients with cancer of endometrium which produced acute renal failure during Pembrolizumab + Lenvatinib therapy 宇田竜也, 白川直人, 岡部風葉, 高橋未來, 森下美希, 中田和宏, 木村美由喜 Journal of Japanese Society of Pharmaceutical Oncology 30: 292-292, 2023. |
|---|
|
|
P-073. The case that suggested addition of the camostat mesilate for a reflux oesophagitis symptom found after the gastric cancer total gastrectomy 澤井一1), 赤嶺美奈1,2), 赤嶺有希子2), 加納美知子1,2), 高木正信1,2), 田中祥子1,2), 寺腰梓1,2), 松尾律子1,2), 姜惠元1), 吉原澄吉3), 谷田弘3) Journal of Japanese Society of Pharmaceutical Oncology 30: 293-293, 2023. |
|---|
|
|
P-074. The case that we suggested cranberry jelly for UTIs to repeat ovarian cancer postoperative revival, and an effect was obtained 加納美知子1,2), 石津剛志3), 脇田実南4), 赤嶺美奈1,2), 赤嶺有希子2), 高木正信1,2), 田中祥子1,2), 寺腰梓1,2), 松尾律子1,2), 姜惠元5), 吉原澄吉5), 谷田弘5), 澤井一1) Journal of Japanese Society of Pharmaceutical Oncology 30: 294-294, 2023. |
|---|
|
|
P-075. Case corresponding to the supplement intake consultation of patients with breast cancer during the tamoxifen remedy 田中祥子1,2), 伊藤誠3), 青木美紀4), 赤嶺美奈1,2), 赤嶺有希子1), 加納美知子1,2), 高木正信1,2), 寺腰梓1,2), 松尾律子1,2), 姜惠元2), 吉原澄吉5), 谷田弘5), 澤井一2) Journal of Japanese Society of Pharmaceutical Oncology 30: 295-295, 2023. |
|---|
|
|
P-076. A side effect evaluation and monitoring of the preoperative chemotherapy for patients with breast cancer with the mental disorder 田中雅宏 Journal of Japanese Society of Pharmaceutical Oncology 30: 296-296, 2023. |
|---|
|
|
P-077. Cholinergic symptom - with one - irinotecan hydrochloride that supportive care of the intravenous feeding anticancer medicine led to addition by the reporting from the health insurance pharmacy 松本剛, 立澤明 Journal of Japanese Society of Pharmaceutical Oncology 30: 297-297, 2023. |
|---|
|
|
P-078. An effect of the dose-dense EC therapy in our hospital and safe investigation 遠藤秀竜, 加藤貴由, 中島彩子, 見尾谷昇, 山崎崇 Journal of Japanese Society of Pharmaceutical Oncology 30: 298-298, 2023. |
|---|
|
|
P-079. One case that came by treatment continuation after the recurrence for patients after the rectal cancer technique which developed prerenal acute renal failure after the oral pyrimidine remedy fluoride in mFOLFOX6 + BEV 大木崇弘1), 大澤愛1), 森山岳1), 勝田大貴1), 芝崎由美子1), 塩谷猛2) Journal of Japanese Society of Pharmaceutical Oncology 30: 299-299, 2023. |
|---|
|
|
P-080. The intervention case that led from the residual drug in the pouch of the Ostomate to a dosage form change 和田祥一 Journal of Japanese Society of Pharmaceutical Oncology 30: 300-300, 2023. |
|---|
|
|
P-081. One case that dealt that a drugstore pharmacist in connection with a specialized medical institution cooperation drugstore notices lacrimal possibility by S-1, and is appropriate 師橋一徳 Journal of Japanese Society of Pharmaceutical Oncology 30: 301-301, 2023. |
|---|
|
|
P-082. One case that we introduced prednisolone for interstitial nephritis with the nivolumab + ipilimumab therapy, and adrenal insufficiency occurred after the gradual decrease, the cancellation 吉田憲司1), 橋本知世1), 赤井涼子1), 高木賢治2), 八木一騎3), 岡田栄子4), 矢吹直寛4) Journal of Japanese Society of Pharmaceutical Oncology 30: 302-302, 2023. |
|---|
|
|
P-083. Case report about the Rikkunshito prescribed for appetite decreased after the gastric cancer surgery 高木正信1,2), 中原真祐子5), 羽田啓吾4), 赤嶺美奈1,2), 赤嶺有希子1), 加納美知子1,2), 姜恵恩1,2), 田中祥子1,2), 寺腰梓1,2), 堀泰葉1), 松尾律子2), 吉原澄吉3), 谷田弘3), 澤井一2) Journal of Japanese Society of Pharmaceutical Oncology 30: 303-303, 2023. |
|---|
|
|
P-084. 1 case that performed the prevention and measures about high blood pressure, a hand-and-foot syndrome by the Cabozantinib, and led to internal use continuation 大野雅斗, 米倉正樹, 丹羽直人 Journal of Japanese Society of Pharmaceutical Oncology 30: 304-304, 2023. |
|---|
|
|
P-085. Example that was able to continue treatment by adjustment of the nutrition therapy for a disorder to pass the esophagus by the reason except the condition of a patient progression that occurred during cancer of the esophagus chemotherapy 岸本真1,2,4), 中村杏果1,4), 森永崇史1), 岩元美樹1,2,4), 徳永楓果1), 米田仁保1), 池沢若菜1), 田中恭人1,2,4), 豊留麻衣1,4), 北園幸大1), 中野一馬1,4), 山本梢1,4), 屋敷大輔1,2), 淵脇ゆかり1), 徳丸章佳1), 長ヶ原琢磨1), 荻尾夕起子1), 濱田浩子1,3,4) Journal of Japanese Society of Pharmaceutical Oncology 30: 305-305, 2023. |
|---|
|
|
P-086. The case that was able to affect the side effect management in the pazopanib 菅野義晃, 佐藤貴子, 佐藤博泰, 佐藤美緒, 野崎友佑, 三上麻子, 齊藤賢一 Journal of Japanese Society of Pharmaceutical Oncology 30: 306-306, 2023. |
|---|
|
|
P-087. Suspect onset of heart failure by the periodical telephone follow to patients with breast cancer, and suggest monitoring of the cardiac activity to a physician; for early detection 赤嶺美奈1,2), 赤嶺有希子1), 加納美知子1,2), 高木正信1,2), 田中祥子1,2), 寺越梓1,2), 堀泰羽1), 松尾律子2), 吉原澄吉3), 谷田弘3), 澤井一2) Journal of Japanese Society of Pharmaceutical Oncology 30: 307-307, 2023. |
|---|
|
|
P-088. A case of multiple myeloma with Carfilzomib-induced heart disorder 中村あゆみ, 打矢貴子, 鈴木亮平, 溝口和代, 高橋昌明 Journal of Japanese Society of Pharmaceutical Oncology 30: 308-308, 2023. |
|---|
|
|
P-089. An example of inability to curative resection progress pancreas head cancer that resulted in hyperammonemia due to high-dose 5-FU after the mFOLFIRINOX therapy enforcement 近藤潤一, 谷垣柊乃介, 尾田未来, 笹瀬優斗, 津野丈彦, 小杉三弥子, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 30: 309-309, 2023. |
|---|
|
|
P-090. Antiemetic therapy in Lutetium(177Lu)oxodotreotide administration 田中慎1), 高松宏行1), 舟越亮寛1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 310-310, 2023. |
|---|
|
|
P-091. 1 case that was connected with the improvement of the retching symptom by a drugstore pharmacist grasping the state of patients by periodical telephone follow, and giving information to a medical institution 矢部和昭1), 藤田あゆみ2), 杉浦伸哉2) Journal of Japanese Society of Pharmaceutical Oncology 30: 311-311, 2023. |
|---|
|
|
P-092. Relation in our hospital pharmacist outpatient department for irAE 矢留徹, 弓削理恵子, 佐藤沙紀, 相澤学 Journal of Japanese Society of Pharmaceutical Oncology 30: 312-312, 2023. |
|---|
|
|
P-093. The example that contributed to treatment continuation of the cancer chemotherapy foreign the medication follow-up of the drugstore pharmacist 五十嵐爽1), 木名瀬直樹1), 山口弘1), 常世田京子2), 前田守3), 永野悠馬3), 緒形富雄3), 市ノ渡真史3), 長谷川佳孝3), 月岡良太3), 大石美也3) Journal of Japanese Society of Pharmaceutical Oncology 30: 313-313, 2023. |
|---|
|
|
P-094. The example that contributed to continuation of the foreign cancer chemotherapy that the medication follow-up of the drugstore pharmacist was safe 杉山純子1), 伊藤将2), 永野悠馬2), 前田守2), 緒形富雄2), 市ノ渡真史2), 長谷川佳孝2), 月岡良太2), 大石美也2) Journal of Japanese Society of Pharmaceutical Oncology 30: 314-314, 2023. |
|---|
|
|
P-095. One patient who was able to prevent onset of vasculitis and vascular pain by switching to a method to coadminister a saline and vinorelbine 石井俊一1,2), 市村丈典1,2), 市倉大輔1,2), 阿部誠治1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 315-315, 2023. |
|---|
|
|
P-096. Modi operandi and example report of the patients with cancer telephone follow-up in the beginning drugstore medical shop 中村俊貴1), 爲我井一統1), 坂本岳志1), 境美智順1), 泉玲子2), 糸賀守2), 岡野知子2), 木村雅彦1) Journal of Japanese Society of Pharmaceutical Oncology 30: 316-316, 2023. |
|---|
|
|
P-097. Effect on treatment by drugstore pharmacist intervention continuation in Abemaciclib treated patients 三上寿世 Journal of Japanese Society of Pharmaceutical Oncology 30: 317-317, 2023. |
|---|
|
|
P-098. Example that developed severe peripheral neuropathy by capecitabine single agent administration 古林園子1), 廣田侑真1), 廣瀬健一1), 小沼大祐1), 牧山稔1), 榊原舞2), 筒井秀知1) Journal of Japanese Society of Pharmaceutical Oncology 30: 318-318, 2023. |
|---|
|
|
P-099. Example that was thought to cause the reinforcement of myelosuppression by the albumin suspension type paclitaxel by fluconazole combination 青野由依, 畑裕基, 山本友佳子, 宮城和代, 長谷川英利, 村津圭治, 山下大輔, 吉野宗宏 Journal of Japanese Society of Pharmaceutical Oncology 30: 319-319, 2023. |
|---|
|
|
P-100. 1 case that PT-INR increased during pazopanib remedy in the patients with malignant phyllodes tumor 松本優太1), 平田一耕2,3), 石原達弥1), 小倉宏之3), 北原加奈之3), 舟越良寛3,4) Journal of Japanese Society of Pharmaceutical Oncology 30: 320-320, 2023. |
|---|
|
|
P-101. Cases with adverse events caused by Enfortumab Vedotin 井手飛香1), 稲村由香1), 大野大地2), 木室里依子2), 湊晶規2), 藤本直浩2) Journal of Japanese Society of Pharmaceutical Oncology 30: 321-321, 2023. |
|---|
|
|
P-102. One case of the Olaparib administration for patients with recurrent ovarian cancer with the severeness decreased renal function 吉野走1), 森善洋1), 岩村直矢1), 佐道紳一1), 福田久信2), 小寺宏平2), 樋口則英1) Journal of Japanese Society of Pharmaceutical Oncology 30: 322-322, 2023. |
|---|
|
|
P-103. Skin disorder management of Enfortumab Vedotin 斉藤諒1), 梅原健吾1), 高田慎也1), 山岸佳代1), 原林透2), 丸山覚2), 高田徳容2), 美濃興三1) Journal of Japanese Society of Pharmaceutical Oncology 30: 323-323, 2023. |
|---|
|
|
P-104. A study on the usage status and introduction timing of Anamorelin in our hospital 村嶋彩加, 宗本尚子, 鳥居奈央, 川島悠吾, 松本圭司 Journal of Japanese Society of Pharmaceutical Oncology 30: 324-324, 2023. |
|---|
|
|
P-105. Examination ... of participation in cancer-carrying patient - bevacizumab dosage advisability with the DVT 中島美紀, 塗木勇介, 原竜太郎 Journal of Japanese Society of Pharmaceutical Oncology 30: 325-325, 2023. |
|---|
|
|
P-106. One patient who was able to contribute to the bowel movement improvement of patients who received chemotherapy by the hearing that a drugstore pharmacist was multifaceted and a pharmaceutical evaluation 松本憲昭 Journal of Japanese Society of Pharmaceutical Oncology 30: 326-326, 2023. |
|---|
|
|
P-107. One case that was connected by the multi-type of job cooperation for symptom improvement for oral mucositis 掛札聡美, 畠山卓, 飯嶋歩, 小林美佳 Journal of Japanese Society of Pharmaceutical Oncology 30: 327-327, 2023. |
|---|
|
|
P-108. Fact-finding of the side effect expression situation and Lenvatinib doses with Lenvatinib/Pembrolizumab combination therapy in our hospital 酒井鉄平, 相川晴彦, 内田美伽, 上野正夫 Journal of Japanese Society of Pharmaceutical Oncology 30: 328-328, 2023. |
|---|
|
|
P-109. Intervention of the blood sugar control in patients with diabetes merger cancer utilizing the tracing report 末次加代子1), 藤田あゆみ2), 杉浦伸哉2) Journal of Japanese Society of Pharmaceutical Oncology 30: 329-329, 2023. |
|---|
|
|
P-110. The development report number of immune-mediated adverse events and investigation of the development time 高木淳也, 海野祥生, 前田美紀, 山本恵梨香, 生田和之, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 30: 330-330, 2023. |
|---|
|
|
P-111. Is giving Entrectinib for progress pancreatic cancer; one case who had gait disturbance and pubic bones, the sacrum fractured 景山康二郎1), 田頭尚士1), 西田朋洋1), 山口千尋1), 坂田悠輔4), 田妻昌2), 岡田芳樹3), 藤田秀樹1), 坂本靖之1) Journal of Japanese Society of Pharmaceutical Oncology 30: 331-331, 2023. |
|---|
|
|
P-112. One patient who applied allergy regimen for hypersensitivity reaction of oxaliplatin, and succeeded in treatment continuation 坂井達洋, 青木祥子, 石井貴之 Journal of Japanese Society of Pharmaceutical Oncology 30: 332-332, 2023. |
|---|
|
|
P-113. An example (in the case of an intraoral symptom) of the suggestion of the supportive care in the health insurance pharmacy juxtaposition type drugstore 松下真吾1), 高田智1), 佐高千里1), 野嶋芳紀1), 松尾宗一郎1), 邑瀬誠1), 深津英人2), 松井洸2), 阿部真也2), 山口浩2), 立石大介2), 吉町昌子2), 野村和彦2) Journal of Japanese Society of Pharmaceutical Oncology 30: 333-333, 2023. |
|---|
|
|
P-114. An example (in the case of dermatopathy) of the suggestion of the supportive care in the health insurance pharmacy juxtaposition type drugstore 高田智1), 松下真吾1), 佐高千里1), 野嶋芳紀1), 松尾宗一郎1), 邑瀬誠1), 深津英人2), 松井洸2), 阿部真也2), 山口浩2), 立石大介2), 吉町昌子2), 野村和彦2) Journal of Japanese Society of Pharmaceutical Oncology 30: 334-334, 2023. |
|---|
|
|
P-115. A case of Abemaciclib (Verzenio(R)) introduced in a patient with postoperative recurrence of advanced breast cancer on hemodialysis 富山正也, 福嶋浩一, 野村洋道, 中浴伸二, 田中詳二 Journal of Japanese Society of Pharmaceutical Oncology 30: 335-335, 2023. |
|---|
|
|
P-116. One patient who was able to continue the treatment of the CDK4/6 inhibitor in Palbociclib after the onset of liver damage by the Abemaciclib in the patients with breast cancer 小澤有輝1), 藤宮龍祥2), 嶋田昌彦3), 岡沢啓4), 草野淳一1), 山本龍世1), 林誠一1) Journal of Japanese Society of Pharmaceutical Oncology 30: 336-336, 2023. |
|---|
|
|
P-117. Three cases of acute myeloid leukemia that were able to continue treatment by a drug withdrawal of Venetoclax in combination therapy with Venetoclax/Azacitidine 伊東英子, 新井聡子, 中野涼太, 濱野愛里, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 30: 337-337, 2023. |
|---|
|
|
P-118. A case of administration of Lutetium (177Lu) oxodotreotide to a patient with rectal neuroendocrine tumor complicated by prostate cancer 鈴木秀隆1), 加納大輔1), 望月伸夫1), 大橋周平2), 平田秀成3), 森田敬裕4), 今岡大5), 池田公史5) Journal of Japanese Society of Pharmaceutical Oncology 30: 338-338, 2023. |
|---|
|
|
P-119. Example that switched to methadone during home care for three days 早川晃央 Journal of Japanese Society of Pharmaceutical Oncology 30: 339-339, 2023. |
|---|
|
|
P-120. The current situation of the use of palliation drug in the treatment at home of the AYA generation terminal phase 直井美萌1,5), 山田遥子2,5), 武井大輔1,5), 五木田茶舞3,5), 別府武4,5) Journal of Japanese Society of Pharmaceutical Oncology 30: 340-340, 2023. |
|---|
|
|
P-121. The example that we were able to control that accepted the pain of patients using a portable spirit smuggling liquid pump by treatment at home 馬場章人, 小黒佳代子 Journal of Japanese Society of Pharmaceutical Oncology 30: 341-341, 2023. |
|---|
|
|
P-122. One case that we connected with improvement of the patients quality of life by pain control improvement by opioid switching that a drugstore pharmacist is quick in cooperation with the multi-type of job 徳留智子1), 藤田あゆみ2), 杉浦伸哉2) Journal of Japanese Society of Pharmaceutical Oncology 30: 342-342, 2023. |
|---|
|
|
P-123. The operational report and utilization situation of the foreign cancer chemotherapy tracing report 伊東充, 高橋真一, 向井晴香, 江川朱季, 佐藤香織, 勝俣はるみ Journal of Japanese Society of Pharmaceutical Oncology 30: 343-343, 2023. |
|---|
|
|
P-124. Effect by office worker placement and the injection drug coinfusion inspection system AddDis(R) introduction 虻川詩希子, 畠山陽子, 中居肇 Journal of Japanese Society of Pharmaceutical Oncology 30: 344-344, 2023. |
|---|
|
|
P-125. Effect to give the business efficiency of the anticancer medicine preparation by the Pharmacy Isolator introduction 清水美里, 米北浩人, 藤田淳志, 中村英治 Journal of Japanese Society of Pharmaceutical Oncology 30: 345-345, 2023. |
|---|
|
|
P-126. Efforts to anticancer agent exposure measures to be possible in ethical pharmacy 檀和貴, 平良高大, 山國裕代 Journal of Japanese Society of Pharmaceutical Oncology 30: 346-346, 2023. |
|---|
|
|
P-127. Fact-finding of the anticancer agent exposure to preparation indoor environment 森本智, 原田靖基, 今井秀樹 Journal of Japanese Society of Pharmaceutical Oncology 30: 347-347, 2023. |
|---|
|
|
P-128. Construction of a multidisciplinary medical support system for the use of Anamorelin hydrochloride 井上和洋, 松野知寛, 北村憲雅, 蓮輪博嗣, 横尾賢乗 Journal of Japanese Society of Pharmaceutical Oncology 30: 348-348, 2023. |
|---|
|
|
P-129. Examination of the environmental exposure measures of the anticancer agent using the hypochlorous acid water solution 草野淳一, 山本龍世, 矢吹優, 小澤有輝, 伊藤智一, 吉田理, 林誠一 Journal of Japanese Society of Pharmaceutical Oncology 30: 349-349, 2023. |
|---|
|
|
P-130. Lutetium (177Lu) oxodotreotide pharmacist's efforts in supply and management 高松宏行1), 田中慎1), 舟越亮寛1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 350-350, 2023. |
|---|
|
|
P-131. Safe elimination and efficiency by the CSTD entire surface development 向井光一朗, 東久美子 Journal of Japanese Society of Pharmaceutical Oncology 30: 351-351, 2023. |
|---|
|
|
P-132. Efforts of the pharmacist using the cancer chemotherapy check sheet 赤星璃, 栗崎貴啓 Journal of Japanese Society of Pharmaceutical Oncology 30: 352-352, 2023. |
|---|
|
|
P-133. Introduction and evaluation of the type I diabetes mellitus measures protocol with the immune checkpoint inhibitor 畠山智明, 鈴木拓也, 遠藤美央, 玉木慎也 Journal of Japanese Society of Pharmaceutical Oncology 30: 353-353, 2023. |
|---|
|
|
P-134. The anticancer agent exposure situation and problems after the closed system anesthesia drug transportation system introduction expansion 岩松真理香, 藤井克知, 加藤剛志, 坂口貴大, 斎藤和悦 Journal of Japanese Society of Pharmaceutical Oncology 30: 354-354, 2023. |
|---|
|
|
P-135. Attitude survey about the exposure situation investigation in the anticancer medicine preparation environment and the exposure 永田菜美子1), 榊原辰弥1), 後藤真実1), 若林茜1), 池内晶哉1), 片山宏章2), 篠道弘1) Journal of Japanese Society of Pharmaceutical Oncology 30: 355-355, 2023. |
|---|
|
|
P-136. About the efficiency of the duties that we were able to see from an intervention example in the foreign chemotherapy of the lung cancer 永見恵里奈, 植木大介, 橋本若奈, 船崎秀樹, 千田昌之 Journal of Japanese Society of Pharmaceutical Oncology 30: 356-356, 2023. |
|---|
|
|
P-137. An evaluation after the PBPM introduction for anticancer agent proper use and prospects in the future 藤田憲一, 宮本京介, 亀岡大樹, 山川将之, 章勇気, 杉山健二郎, 河相景子, 家岡昌弘, 桑田益希 Journal of Japanese Society of Pharmaceutical Oncology 30: 357-357, 2023. |
|---|
|
|
P-138. The doubt inquiry situation investigation in our hospital and future problem 山関智恵, 三浦毅 Journal of Japanese Society of Pharmaceutical Oncology 30: 358-358, 2023. |
|---|
|
|
P-139. It is examined the dissolution method for shortening at oil xanthan gum (R) time to redissolve it 野口善久, 土居真純, 床西冴月, 中原菜乃美, 堀果子 Journal of Japanese Society of Pharmaceutical Oncology 30: 359-359, 2023. |
|---|
|
|
P-140. Follow-up report by the pharmacist who obtained PRO-CTCAE(TM) of patients with cancer continuously electronically 廣田峻一1), 水野喜暁2) Journal of Japanese Society of Pharmaceutical Oncology 30: 360-360, 2023. |
|---|
|
|
P-141. Examination about the effect contracted at the nab-PTX preparation time using the closed system anesthesia drug transfusion system 根路銘真歩, 有井大介, 千葉愛珠, 大谷拓也 Journal of Japanese Society of Pharmaceutical Oncology 30: 361-361, 2023. |
|---|
|
|
P-142. Questionnaire ... to an authorization acquisitor associated with attitude survey - cancer medical therapy about the usefulness of the video explanation material of the anticancer medicine in the inpatient 佐藤美樹1), 清水久範2), 山端悠介2), 鈴木亘2), 橋本幸輝2), 副島梓2), 友松拓哉2), 小林一男2), 川上和宜2), 横川貴志2), 平出誠1), 鳥越一宏1), 鈴木賢一1), 山口正和2) Journal of Japanese Society of Pharmaceutical Oncology 30: 362-362, 2023. |
|---|
|
|
P-143. Influence on the number of Preventing and avoiding cases by workshops at pharmacies affiliated with specialized medical institutions 植竹友輔 Journal of Japanese Society of Pharmaceutical Oncology 30: 363-363, 2023. |
|---|
|
|
P-144. Questionnaire ... to an authorization acquisitor associated with attitude survey - cancer medical therapy about the usefulness of the video explanation material of the anticancer medicine in the outpatient 碓氷はるか1), 清水久範2), 小林一男2), 川上和宜2), 鈴木亘2), 横川貴志2), 橋本幸輝2), 副島梓2), 友松拓哉2), 山端悠介2), 平出誠1), 鳥越一宏1), 鈴木賢一1), 山口正和2) Journal of Japanese Society of Pharmaceutical Oncology 30: 364-364, 2023. |
|---|
|
|
P-145. The effect that supply restrictions of the nab-Paclitaxel preparation gave in the choice of the regimen 矢田部恵, 小川千晶, 工藤彰, 大塚健太郎, 長山佳之, 石嶋麗, 今村有那, 武重彩子, 谷健太郎, 吉川至, 大塚知信 Journal of Japanese Society of Pharmaceutical Oncology 30: 365-365, 2023. |
|---|
|
|
P-146. It is ... for investigation - PBPM introduction of the intervention contents of the pharmacist in the chemotherapy room 小泉充, 前島光廣, 高野耕一郎, 長谷部晃, 米山尚希 Journal of Japanese Society of Pharmaceutical Oncology 30: 366-366, 2023. |
|---|
|
|
P-147. Efforts for the intervention promotion to foreign cancer instruction to patient of our hospital 畠山卓, 飯嶋歩, 掛札聡美, 小林美佳 Journal of Japanese Society of Pharmaceutical Oncology 30: 367-367, 2023. |
|---|
|
|
P-148. Efforts in our hospital accompanied with the supply stop of the paclitaxel (albumin suspension type) 山口大樹, 島貫裕実子, 大橋養賢, 渡邊一史, 小室雅人, 増田純一, 西村富啓 Journal of Japanese Society of Pharmaceutical Oncology 30: 368-368, 2023. |
|---|
|
|
P-149. About effect on cancer chemotherapy enforcement under the COVID-19 outbreak 小島菜緒1), 川田亮1), 浜島一代2) Journal of Japanese Society of Pharmaceutical Oncology 30: 369-369, 2023. |
|---|
|
|
P-150. Duties improvement ... by non-order information extraction of foreign chemotherapy patients and the utilization of table making - DWH and the ME macro-function 鶴田瑞葵1), 武藤浩司1), 細井仁2), 田中裕子1) Journal of Japanese Society of Pharmaceutical Oncology 30: 370-370, 2023. |
|---|
|
|
P-151. The current situation and evaluation of the "my clinical record ONC" for continuous side effect "remote" monitoring introduction 安部圭紀, 辻茉莉香, 溝口明子, 塚川麻理子, 佐藤弘子, 五十嵐文, 高橋賢成 Journal of Japanese Society of Pharmaceutical Oncology 30: 371-371, 2023. |
|---|
|
|
P-152. Pulse-taking of the tracing report in the specialized medical institution cooperation drugstore 伊津田知樹1), 藤田あゆみ2), 盛岡洋平1), 見越聖也1), 赤尾美乃里1), 杉浦伸哉2), 杉浦克典2) Journal of Japanese Society of Pharmaceutical Oncology 30: 372-372, 2023. |
|---|
|
|
P-153. The need of the telephone follow-up that continued that is twice a month for foreign cancer-treated patients: Case report 坂本岳志1), 中村俊貴1), 爲我井一統1), 境美智順2), 木村雅彦3) Journal of Japanese Society of Pharmaceutical Oncology 30: 373-373, 2023. |
|---|
|
|
P-154. It is ... through the cooperation of efforts - pharmacist and the dietician to outpatient department cancer chemotherapy with high quality in our hospital 樋口理恵1), 村上幸恵1), 山本剛1), 高橋洋平2) Journal of Japanese Society of Pharmaceutical Oncology 30: 374-374, 2023. |
|---|
|
|
P-155. The inflection situation of the community medical care cooperation network service in the cancer medical therapy at the health insurance pharmacy 田中寿和, 堀龍太郎, 高嶋優太, 武田照幸, 西澤健太, 横井飛太, 木下隆市, 染谷光洋, 宮岡勝弘, 谷口亮央, 中島史雄 Journal of Japanese Society of Pharmaceutical Oncology 30: 375-375, 2023. |
|---|
|
|
P-156. One patient who reduced going to hospital and an economic burden by the reporting from the health insurance pharmacy, and was able to continue treatment 立澤明, 松本剛 Journal of Japanese Society of Pharmaceutical Oncology 30: 376-376, 2023. |
|---|
|
|
P-157. Questionary survey about the reporting to the health insurance pharmacy in the cooperation full addition 野場悠司, 喜古康博, 佐藤大祐, 伊藤駿, 塩原慶徳, 杉崎涼子 Journal of Japanese Society of Pharmaceutical Oncology 30: 377-377, 2023. |
|---|
|
|
P-158. Problems from the low reply rate of the tracing report to the current situation and the medicine medicine cooperation that we were able to see 藤村裕司1), 下村香菜1), 栗原直貴1), 櫻井美月1), 兼子さやか1), 野崎千暁1), 本木龍二1), 田村賢士1), 金子誠1), 赤沼浩明1), 立花栄三1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 378-378, 2023. |
|---|
|
|
P-159. About the tracing report operation situation with the health insurance pharmacy using Dr.JOY in the foreign cancer chemotherapy in our hospital 栗原りか, 濱中悠賀, 新行内健一, 伊藤博, 金井貴充 Journal of Japanese Society of Pharmaceutical Oncology 30: 379-379, 2023. |
|---|
|
|
P-160. Cancer chemotherapy regimen inspection by the injection formulations support system introduction and efforts to cooperation full addition calculation 原田真由美, 石井紀子, 市川卓哉, 益子里美 Journal of Japanese Society of Pharmaceutical Oncology 30: 380-380, 2023. |
|---|
|
|
P-161. The example that led to intervention, medicine medicine cooperation to team approach in medical care than the pharmacist training specialized in local pharmacy care, palliative care conference 福島岳 Journal of Japanese Society of Pharmaceutical Oncology 30: 381-381, 2023. |
|---|
|
|
P-162. Maintenance and efforts - first ... of the system for the rescue drug self-care introduction 高屋麻由, 市原英則, 音羽美貴, 庄野裕志, 畝佳子 Journal of Japanese Society of Pharmaceutical Oncology 30: 382-382, 2023. |
|---|
|
|
P-163. Duties investigation of the exclusive duty pharmacist in the foreign chemotherapy room 宍倉啓介, 五月女千草, 山口智 Journal of Japanese Society of Pharmaceutical Oncology 30: 383-383, 2023. |
|---|
|
|
P-164. Questionary survey and duties improvement about the medical cooperation in the foreign cancer medical therapy 今井洋志, 加賀麻友美, 門田佳子 Journal of Japanese Society of Pharmaceutical Oncology 30: 384-384, 2023. |
|---|
|
|
P-165. Usefulness evaluation of the medical cooperation by PBPM using STAS-J for the use of drug patients for the medical care 徳永愛美1,2), 縄田修一1,2), 日向美羽1,2), 磯崎遥1,2), 田中茜1,2), 村田勇人3), 松田枝里3), 市原絢子3), 菅美佳4) Journal of Japanese Society of Pharmaceutical Oncology 30: 385-385, 2023. |
|---|
|
|
P-166. Evaluation of the clinical usefulness of the cooperation system before and after the practice type workshop holding using the tracing report about the foreign cancer chemotherapy 酒井由希子1), 川村真理恵1), 柳田義一1), 小川好美2), 三枝隼樹3), 石井豪4), 谷口綾子5) Journal of Japanese Society of Pharmaceutical Oncology 30: 386-386, 2023. |
|---|
|
|
P-167. The acquisition situation of the cooperation full addition in the foreign cancer chemotherapy of our hospital and the evaluation 小山加奈世, 阿部史誉, 早川太朗 Journal of Japanese Society of Pharmaceutical Oncology 30: 387-387, 2023. |
|---|
|
|
P-168. Efforts of the medicine medicine cooperation through the RevMate recognition degree investigation 渡邉佑奈1), 清水幸宏2), 中村枝里1), 阿部一代1), 関川大輔1), 土居ひろみ1), 丸山杏里1), 堀内俊克2), 佐藤裕之1) Journal of Japanese Society of Pharmaceutical Oncology 30: 388-388, 2023. |
|---|
|
|
P-169. The current situation evaluation of the medicine medicine cooperation using the tracing report associated with the cancer medical therapy 林由紀子1), 高谷甲波1), 篠崎聡1), 郡妙恵1), 原木美緒2), 新田茜1), 乾佐登子1), 本多秀俊1), 鮎川みゆき2), 並木路広1) Journal of Japanese Society of Pharmaceutical Oncology 30: 389-389, 2023. |
|---|
|
|
P-170. About the introduction of the irAE measures medicine medicine cooperation tool in the Kure district 田頭尚士1), 西田朋洋1), 景山康二郎1), 坂本靖之1), 大塚茂雄2), 鷹橋紀幸2), 大塚幸三2), 藤田秀樹1) Journal of Japanese Society of Pharmaceutical Oncology 30: 390-390, 2023. |
|---|
|
|
P-171. Efforts of the pharmaceutical management of the foreign chemotherapy patients utilizing the tracing report and the evaluation 鈴木健太, 原幸稔, 松本大吾, 仙波秀彦, 三宮忠 Journal of Japanese Society of Pharmaceutical Oncology 30: 391-391, 2023. |
|---|
|
|
P-172. Discharge drug information cooperation to the community pharmacy utilizing "drug control summary" 中村博雄, 伊藤綾子, 加藤芽衣, 佐々木由佳, 野田あす花, 横井亜也奈, 加藤真治, 伊藤陽一 Journal of Japanese Society of Pharmaceutical Oncology 30: 392-392, 2023. |
|---|
|
|
P-173. The template making of the tracing report for the foreign chemotherapy and examination of the usefulness 圓藤晶子, 佐々木香奈 Journal of Japanese Society of Pharmaceutical Oncology 30: 393-393, 2023. |
|---|
|
|
P-174. Problems of the information sharing to depend on the cooperation full addition 伊與田友和1,2), 菅野雅仁1), 黒田純子1) Journal of Japanese Society of Pharmaceutical Oncology 30: 394-394, 2023. |
|---|
|
|
P-175. Questionary survey about patients during treatment with anticancer agent in the medicine medicine cooperation 飯嶋歩, 掛札聡美, 畠山卓, 小林美佳 Journal of Japanese Society of Pharmaceutical Oncology 30: 395-395, 2023. |
|---|
|
|
P-176. Fact-finding of the reporting in foreign cancer treatment and examination about report contents 林哲哉, 阿部多一, 住谷達也, 井口恵美子 Journal of Japanese Society of Pharmaceutical Oncology 30: 396-396, 2023. |
|---|
|
|
P-177. 2 cases that utilized a telephone support tracing report based on ICT, and conducted pharmaceutical intervention by a hospital, drugstore collaboration patient monitoring 井上靖隆1), 宍戸桃子1), 阿部みさき2), 山崎友里絵3), 鈴木直哉3), 比嘉耕基3), 加納宏樹1), 川本由加里1), 中村路夫4), 後藤仁和1) Journal of Japanese Society of Pharmaceutical Oncology 30: 397-397, 2023. |
|---|
|
|
P-178. About the after follow at the health insurance pharmacy that changed by regimen mention to a prescription 森祐一郎, 宮本麻里, 喜井裕子, 清水由美, 藤吉有希子, 青木すみれ, 好光恵美子 Journal of Japanese Society of Pharmaceutical Oncology 30: 398-398, 2023. |
|---|
|
|
P-179. The case that led to RevMate(R) observance of lenalidomide in cooperation with a health insurance pharmacy pharmacist 吉田孝1), 大野利紗2), 杉本彩子2), 加藤良治1) Journal of Japanese Society of Pharmaceutical Oncology 30: 399-399, 2023. |
|---|
|
|
P-180. The current situation of the medicine medicine cooperation for the foreign cancer chemotherapy after the cooperation full addition calculation start 佐野嘉容子, 片桐将志, 篠永浩, 原田典和, 加地努 Journal of Japanese Society of Pharmaceutical Oncology 30: 400-400, 2023. |
|---|
|
|
P-181. Fact-finding and problem of the tracing report from the health insurance pharmacy in our hospital outpatient department chemotherapy patients 金正興1), 縄田修一1,2), 仁尾祐太1,2), 古久保優衣3), 黄田明日香3), 田中佐知子3), 嶋村弘史1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 401-401, 2023. |
|---|
|
|
P-182. Result and problem by the cooperation full addition calculation start 海野祥生, 生田和之, 高木淳也, 前田美紀, 山本恵梨香, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 30: 402-402, 2023. |
|---|
|
|
P-183. What is demanded from hospital pharmacist in the medicine medicine cooperation of foreign cancer treatment 阿蘇拡樹, 神隆浩, 鈴木郁也, 萩原智暉, 大木稔也 Journal of Japanese Society of Pharmaceutical Oncology 30: 403-403, 2023. |
|---|
|
|
P-184. Examination ... of the usefulness of efforts - specific drug management instruction addition 2 of the drugstore pharmacist for foreign cancer chemotherapy patients 四方晴美1), 佐藤圭1), 澤谷真希1), 高田聖子1), 田宮雅子1), 中村瑠璃1), 廣奥智恵1), 森椿1), 山本亘汰1), 洞赳瑠1), 宮本牧子1), 名達陽一1), 五十嵐栄一2) Journal of Japanese Society of Pharmaceutical Oncology 30: 404-404, 2023. |
|---|
|
|
P-185. Fact-finding about the community medical care cooperation, and the like in foreign cancer treatment 石原由起子1,13), 高橋郷2,13), 本田泰斗3,13), 飯塚雄次4,13), 佐々木駿一5,13), 浮谷聡6,13), 盛川敬介7,13), 餅原弘樹8,13), 内坪敬太9,13), 田島亮10,13), 濃沼政美11,13), 松井礼子12,13) Journal of Japanese Society of Pharmaceutical Oncology 30: 405-405, 2023. |
|---|
|
|
P-186. Efforts of the pharmacist in chemotherapy Committee of our hospital 田中智也, 柳原一樹, 樋本繭子, 新免徹, 高瀬尚武 Journal of Japanese Society of Pharmaceutical Oncology 30: 406-406, 2023. |
|---|
|
|
P-187. The current situation investigation and problem of the cooperation full addition in the Fukuyama Municipal Hospital 岩村高弘, 森光保武, 藤井秀一 Journal of Japanese Society of Pharmaceutical Oncology 30: 407-407, 2023. |
|---|
|
|
P-188. Authorized acquisition situation and problem ... multicenter questionary survey second report ... of the specialized medical institution cooperation drugstore in Osaka 西村香奈1,16), 槙原克也2,16), 基村佳世2,16), 福井梨乃2,16), 野見山芳裕3,16), 吉留実慧子4,16), 山口恵5,16), 井上聖夜子6,16), 橋本一代7,16), 富永由美8,16), 喜田博美9,16), 奥澤文敏2,16), 平尾昂士1,16), 伊戸郷美10,16), 中野文仁11,16), 倉田由紀子12,16), 吉岡幸洋13,16), 大森由子14,16), 宮田憲一15,16) Journal of Japanese Society of Pharmaceutical Oncology 30: 408-408, 2023. |
|---|
|
|
P-189. The current situation investigation of the illness medicine cooperation using the cooperation sheets, and the like in foreign cancer chemotherapy patients 及川淳, 木村周古, 及川嵩人, 城戸直人, 西村忠晃, 高橋宏明, 高橋慎太郎, 及川はるか, 佐藤あゆみ, 前川紘也, 熊谷範之, 佐藤文勇, 多田光知子, 奥尚 Journal of Japanese Society of Pharmaceutical Oncology 30: 409-409, 2023. |
|---|
|
|
P-190. Try to efforts through the cancer medicine medicine cooperation in the Matsumoto area 巣山悟1), 淺野未代子2), 中村久美1), 鬼窪利英1) Journal of Japanese Society of Pharmaceutical Oncology 30: 410-410, 2023. |
|---|
|
|
P-191. The current situation investigation about the mention contents of the tracing report and the subsequent course 松本光司, 川上ありす, 奥富彩乃, 牛来瑠菜, 松永佳子 Journal of Japanese Society of Pharmaceutical Oncology 30: 411-411, 2023. |
|---|
|
|
P-192. Patients with cancer supportive care using the commercial drug, side effect management 米良千春 Journal of Japanese Society of Pharmaceutical Oncology 30: 412-412, 2023. |
|---|
|
|
P-193. Examination of the optimal preparation method of Blinatumomab (prepared every 3.5 days) 山極恒平, 武田啓子, 仲井彩華, 西俊明, 石合徹也 Journal of Japanese Society of Pharmaceutical Oncology 30: 413-413, 2023. |
|---|
|
|
P-194. Phase II study (Study protocol of TCRACC study) about the protective efficacy of the hydrocortisone drug for external use for the Capecitabine-induced hand-and-foot syndrome 飯村洋平1), 古川直樹1), 石橋正祥1), 流石智恵子1), 馬場啓介2), 阿彦友佳3,4), 小野山温那3,4), 柵山尚紀3,4), 愛甲丞3,4), 志田大3,4), 野島正寛5), 黒田誠一郎1), 朴成和2) Journal of Japanese Society of Pharmaceutical Oncology 30: 414-414, 2023. |
|---|
|
|
P-195. Making of the CARE check list Japanese edition of the information that you should include when you write case report 藤宮龍祥1), 川口崇1), 北原加奈之2), 上塚朋子3), 宮田靖志4), 岸田直樹5), 益山光一6) Journal of Japanese Society of Pharmaceutical Oncology 30: 415-415, 2023. |
|---|
|
|
P-196. Fix the eyes on questionary survey - job area development to affect the health-related quality of life evaluation by the health insurance pharmacy pharmacist; and - 高橋健市1), 辻将成2), 吉村朋展3), 佐藤莉沙4), 村田勇人5), 梅森菜穂子5), 前原央奈6), 橋本幸輝4), 平松亜依4), 市村丈典7), 清水久範4), 弓削吏司8) Journal of Japanese Society of Pharmaceutical Oncology 30: 416-416, 2023. |
|---|
|
|
P-197. About the change of drug costs after the bevacizumab bio follower product introduction 屋敷大輔1), 徳永楓果1), 米田仁保1), 中村杏果1), 森永崇史1), 池沢若菜1), 田中恭人1), 豊留麻衣1), 岩元美樹1), 北園幸大1), 中野一馬1), 山本梢1), 淵脇ゆかり1), 徳丸章佳1), 長ヶ原琢磨1), 荻尾夕起子1), 平賀翔大2), 岸本真1) Journal of Japanese Society of Pharmaceutical Oncology 30: 417-417, 2023. |
|---|
|
|
P-198. Investigation on the cause of drug solution leakage from the filter during administration of Blinatumomab using a portable precision infusion pump 高野めぐみ1), 池田優子1), 景秀典1), 井野川徹1), 井上元基2), 中舘和彦3), 安武夫4), 津田泰正1), 後藤一美1) Journal of Japanese Society of Pharmaceutical Oncology 30: 418-418, 2023. |
|---|
|
|
P-199. Additional report on outpatient cancer chemotherapy interventions by outpatient pharmacists - Influence of years of experience in cancer treatment on prescription support acceptance rate - 加藤水月, 中野悠馬, 品田似奈, 関口朝美, 大野豊 Journal of Japanese Society of Pharmaceutical Oncology 30: 419-419, 2023. |
|---|
|
|
P-200. Comparison of the foreign chemotherapy addition after the 2022 medical service fees revision 土居真純1), 野口善久1), 床西冴月1), 中原菜乃美1), 堀果子1), 藤本るり子2), 川尻成美3) Journal of Japanese Society of Pharmaceutical Oncology 30: 420-420, 2023. |
|---|
|
|
P-201. The making of the hospital preparation perospirone suppository for the delirium patients and case series report about clinical evaluations 藤本泰輔1), 梅田鈴香1), 塚越真由美3), 田中怜4,5), 佐藤淳也1,2) Journal of Japanese Society of Pharmaceutical Oncology 30: 421-421, 2023. |
|---|
|
|
P-202. Fact-finding about hospital pharmacist duties and the regional alliances of the cancer domain in the 2022 cancer practice cooperation base Hospital, and the like 飯塚雄次1,13), 高橋郷2,13), 本田泰斗3,13), 佐々木駿一4,13), 浮谷聡5,13), 盛川敬介6,13), 餅原弘樹7,13), 内坪敬太8,13), 田島亮9,13), 石原由起子10,13), 濃沼政美11,13), 松井礼子12,13) Journal of Japanese Society of Pharmaceutical Oncology 30: 422-422, 2023. |
|---|
|
|
P-203. Analysis about the JASPO start-up brushing up seminar 2021 seminar contents by the free word mention pattern questionnaire 寺薗英之1,2), 吉川直樹2,3), 小川大介2,4), 森理保2,5), 土屋雅美2,6), 牧陽介2,7), 板垣文雄2,8), 河原陽介2,9), 西村佳子2,10), 篠原佳祐2,11), 岩本義弘2,12), 益子寛之2,13), 米村雅人2,12), 内田まや子2,14) Journal of Japanese Society of Pharmaceutical Oncology 30: 423-423, 2023. |
|---|
|
|
P-204. The effect that the preparation expansion with the closed system anesthesia drug transportation system gives for preparation time and the income and expenditure change 松浦徹, 與田賢作, 中徳有理香, 奥野美和, 鈴木紀子, 山本貴一, 渡邊裕之 Journal of Japanese Society of Pharmaceutical Oncology 30: 424-424, 2023. |
|---|
|
|
P-205. Environmental monitoring investigation of the anticancer medicine in our hospital 小林亜生, 谷川大夢, 湯浅貴裕, 曽根敦子, 鴨川七重, 大間知謙, 平綿洋子, 丸谷善紀, 鈴木優司 Journal of Japanese Society of Pharmaceutical Oncology 30: 425-425, 2023. |
|---|
|
|
P-206. It is a support request contents investigation for a consciousness change to the authorized acquisition by the e-mail magazine issuance for the purpose of the authorized acquisition enlightenment and the authorized acquisition for regional pharmacists 金子美智子, 田中怜, 森本重輝, 村上ひろみ, 篠道弘 Journal of Japanese Society of Pharmaceutical Oncology 30: 426-426, 2023. |
|---|
|
|
P-207. Medical expenses reduction effect by the azacitidine generic macroscale standard vial introduction 宇佐美英績, 木村美智男, 浅野裕紀, 吉村知哲 Journal of Japanese Society of Pharmaceutical Oncology 30: 427-427, 2023. |
|---|
|
|
P-208. Examination of anticancer medicine exposure investigation and measures by the use of sodium hypochlorite 東敬太, 小林美奈子, 唐芳浩太, 梅内実穂, 猪俣結衣, 鈴木訓史, 内藤義博 Journal of Japanese Society of Pharmaceutical Oncology 30: 428-428, 2023. |
|---|
